Document:

<PAGE>

                                                                   EXHIBIT 4.16

                        BIONUMERIK PHARMACEUTICALS, INC.

                 CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

                                NOVEMBER 4, 2004

<PAGE>

                        BIONUMERIK PHARMACEUTICALS, INC.

                 CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

      This Convertible Preferred Stock Purchase Agreement (this "Agreement") is
entered into as of the 4th day of November, 2004, by and between BioNumerik
Pharmaceuticals, Inc., a Texas corporation (the "Company"), and Takeda
Pharmaceutical Company Limited, a Japanese company ("Takeda").

      WHEREAS, the Company and Takeda have entered into that certain License and
Development Alliance Agreement, dated October 5, 2004 (the "Alliance
Agreement"), pursuant to which Takeda has agreed to acquire from the Company,
and the Company has agreed to issue to Takeda, Series I and Series J Convertible
Preferred Stock of BioNumerik, in accordance with the terms and subject to the
conditions set forth herein;

      NOW, THEREFORE, for the consideration described herein and upon the terms
listed below, the parties hereto agree as follows:

ARTICLE 1. AGREEMENT TO ISSUE AND ACQUIRE.

      1.1 AUTHORIZATION OF STOCK. Pursuant to and in accordance with the terms
of Section 8.1 and other pertinent provisions of the Alliance Agreement and upon
the Effective Date (as defined in the Alliance Agreement), the Company has duly
authorized (i) the issuance to Takeda of shares of Series I Convertible
Preferred Stock, par value $0.01 per share, of the Company, (the "Series I
Preferred Stock"), (ii) the issuance to Takeda of shares of Series J Convertible
Preferred Stock, par value $0.01 per share, of the Company, (the "Series J
Preferred Stock" and, collectively or where no distinction is intended with the
Series I Preferred Stock, the "Preferred Shares" and the terms of which two
series of Preferred Stock are attached respectively as Exhibit A), and (iii) the
issuance of such number of shares of its common stock, $0.01 par value per share
("Common Stock"), as shall be, from time to time, issuable upon conversion of
the Preferred Shares in accordance with the terms thereof (the "Conversion
Shares").

      1.2 ISSUANCE. Subject to the terms and conditions hereof, at the closing
of the issuance and purchase of the Preferred Shares under this Agreement (the
"Closing"), the Company hereby agrees to issue to Takeda, and Takeda agrees to
acquire from the Company, the Preferred Shares for an aggregate purchase price
of Fifty-Two Million Dollars (U.S.) ($52,000,000 U.S.) (the "Purchase Price").
The respective number of shares of Series I Preferred Stock and of Series J
Preferred Stock and the respective prices thereof and allocation of the Purchase
Price between Series I Preferred Stock and Series J Preferred Stock shall
initially be as determined pursuant to Section 8.1 of the Alliance Agreement,
subject to adjustment as provided for in Section 8.1 of the Alliance Agreement
and in Exhibit A, in the event of an initial public offering by the Company
within one year of the Closing Date.

                                       1
<PAGE>

ARTICLE 2. CLOSING, DELIVERY AND PAYMENT.

      2.1 CLOSING. The Closing shall take place on November 8, 2004, or such
other date concurrently with the effective date of the Alliance Agreement as the
Company and Takeda may mutually agree (the "Closing Date"). The Closing shall
take place at the Chicago, Illinois offices of Foley & Lardner at 10:00 a.m., or
at such other time or place as the Company and Takeda may mutually agree, on the
Closing Date. If at the Closing any of the conditions specified in Section 5.1
shall not have been fulfilled, Takeda shall, at its election, be relieved of all
of its obligations under this Agreement and the Alliance Agreement without
hereby waiving any other rights it may have by reason of such failure or such
non-fulfillment. If at the Closing, any of the conditions specified in Section
5.2 shall not have been fulfilled, the Company shall, at its election, be
relieved of all of its obligations under this Agreement and the Alliance
Agreement without hereby waiving any other rights it may have by reason of such
failure or such non-fulfillment.

      2.2 DELIVERY. At the Closing, subject to the terms and conditions hereof,
the Company will deliver to Takeda the Preferred Shares, against payment of the
Purchase Price (which shall be by wire transfer of immediately available funds
to the Company).

      2.3 USE OF PROCEEDS. The Company may use the cash proceeds received upon
the issuance of the Preferred Shares at the Closing freely for any valid
corporate purpose without restriction.

ARTICLE 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

      In order to induce Takeda to acquire the Preferred Shares, the Company
hereby represents and warrants to Takeda as follows, except as set forth on the
Disclosure Schedules attached hereto (representations made herein to the
"Knowledge" of the Company means to the actual knowledge after reasonable
investigation of any of the executive officers of the Company identified on
Schedule 3.0) (which will include the Chief Executive Officer and President,
Chief Financial Officer and General Counsel):

      3.1 ORGANIZATION, GOOD STANDING AND AUTHORITY. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Texas and is qualified to do business as a foreign corporation
in each jurisdiction in which such qualification is required, except where the
failure so to qualify would not have a material adverse effect on the business,
assets, liabilities, condition (financial or otherwise), operations or prospects
of the Company (a "Material Adverse Effect"). The Company has all requisite
corporate power and authority to own and operate its properties and assets, to
carry on its business as presently conducted and as proposed to be conducted, to
execute and deliver this Agreement and the Registration Rights Agreement, dated
as of the Closing Date, between the Company and Takeda (the "Registration Rights
Agreement" and, with this Agreement, collectively, the "Transaction Documents"),
and to perform its obligations under each of the Transaction Documents,
including, without limitation, the issuance of the Preferred Shares.

      3.2 AUTHORIZATION; BINDING OBLIGATIONS. All corporate action on the part
of the Company and its officers, directors and shareholders necessary for the
authorization of the Transaction Documents, the performance of all obligations
of the Company hereunder and thereunder at the Closing, and the authorization,
sale, issuance and delivery of the Preferred Shares

                                       2
<PAGE>

and the Conversion Shares pursuant hereto has been taken or will have been taken
prior to the Closing. This Agreement is, and each of the Transaction Documents
is or, when executed and delivered, will be, the valid and binding obligation of
the Company enforceable against it in accordance with its terms, except as
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
other laws of general application affecting enforcement of creditors' rights or
general principles of equity that restrict the availability of equitable
remedies.

      3.3 CAPITALIZATION; VOTING RIGHTS. The authorized capital stock of the
Company (immediately prior to Closing) will consist of (a) 15 million shares of
Common Stock, of which 3,966,838 shares are issued and outstanding and held as
described on Schedule 3.3, and 2,426,997 shares of which are or will be reserved
for issuance to key employees, consultants and others affiliated with the
Company pursuant to BioNumerik's 1993 Stock Option Plan, 1995 Director Stock
Option Plan, 2004 Stock Incentive Plan and Employee Stock Purchase Plan (the
"Equity Incentive Plans"), and (b) 10 million shares of Preferred Stock, $0.01
par value per share (the "Preferred Stock"), the designation, by series, and
number of shares issued and outstanding of which are set forth on Schedule 3.3;
provided, however, that the foregoing capitalization will be subject to
adjustment to give effect to the issuance of shares of Common Stock in
connection with a contemplated initial public offering ("IPO") of Common Stock
by the Company and the resulting automatic conversion of outstanding Preferred
Stock in the event such initial public offering is completed before the Closing
Date. All issued and outstanding shares of the Company's Common Stock and
Preferred Stock have been duly authorized and validly issued, are fully paid and
nonassessable, and were issued in compliance with all applicable state and
federal securities laws. The Conversion Shares have been duly reserved for
issuance. Except as set forth in the Company's Articles of Incorporation, as
amended, or on Schedule 3.3, (i) there are no authorized or outstanding options,
subscriptions, warrants, rights (including conversion or preemptive rights and
rights of first refusal), (ii) the Company has no obligation (contingent or
otherwise) to issue any options, subscriptions, warrants, rights or agreements
of any kind for the purchase or acquisition from the Company of any of its
securities, and (iii) the Company has no obligation (contingent or otherwise) to
purchase, redeem or otherwise acquire any of its securities. When issued in
compliance with the provisions of this Agreement and the designations for the
Series I Preferred Stock and Series J Preferred Stock, as the case may be, the
Conversion Shares will be validly issued, fully paid and nonassessable and will
be free of any liens or encumbrances created by the Company. Schedule 3.3 of the
Disclosure Schedule includes a true and complete summary of the capital stock
and other securities of the Company showing the number of shares of Common or
Preferred Stock, warrants, options or other securities (including convertible
debt, if any). Other than the Transaction Documents and the Alliance Agreement
or as set forth on Schedule 3.3, there are no agreements, written or oral,
between the Company and any holder or prospective holder of the Company's
capital stock or, to the Company's Knowledge, between or among any holders of
the Company's capital stock, relating to the acquisition, disposition, voting or
registration for sale of such capital stock, except those that will have been
waived prior to Closing.

      3.4 SUBSIDIARIES. The Company has no subsidiaries. The Company has no
investment or other interest in, or any outstanding loan or advance to or from,
any Person, including, without limitation, any officer, director or shareholder
of the Company, except for customary travel advances made to employees for
Company travel that are less than $10,000 in the aggregate. As used herein,
"Person" shall mean an individual, corporation, limited liability company,

                                       3
<PAGE>

partnership, joint venture, trust or unincorporated organization or other entity
or a government or agency or political subdivision thereof.

      3.5 GOVERNMENT APPROVALS. The Company has all the material permits,
licenses, orders, franchises and other rights and privileges ("Permits") of all
federal, state, local or foreign governmental or regulatory bodies necessary for
the Company to conduct its business as presently conducted. All such Permits are
in full force and effect and, to the Knowledge of the Company, no suspension or
cancellation of any of them is threatened, and none of such Permits will be
negatively affected by the consummation of the transactions contemplated in this
Agreement and the other Transaction Documents. No consent, approval, license or
authorization of, or designation, declaration or filing with, any court or
governmental authority is or will be required on the part of the Company in
connection with the execution, delivery and performance by the Company of the
Transaction Documents, or in connection with the issuance of the Preferred
Shares or the Conversion Shares, except for (i) those that have already been
made or granted or that will be timely made under applicable securities laws or
with the Texas Secretary of State relating to the transaction set forth herein,
(ii) with respect only to certain registration rights granted under the
Registration Rights Agreement, the filing of registration statements with the
Securities and Exchange Commission (the "Commission") and any applicable state
securities commission as specifically provided for in the Registration Rights
Agreement.

      3.6 FINANCIAL INFORMATION. The audited balance sheets of the Company as of
March 31, 2002, 2003, and 2004 and the related statement of operations for the
years then ended (collectively, the "Audited Financial Statements") were
prepared in accordance with the books and records of the Company and present
fairly in accordance with United States generally accepted accounting
principles, the financial condition and results of operations of the Company as
of the respective dates and for the periods shown. The unaudited balance sheet
of the Company as of June 30, 2004 (the "Balance Sheet Date") and the related
statement of operation for the three-month period then ended (the "Unaudited
Financial Statement" and, together with the Audited Financial Statements,
collectively, the "Financial Statements") were prepared in accordance with the
books and records of the Company and present fairly in accordance with United
States generally accepted accounting principles, the financial condition and
results of operations of the Company as of the respective dates and for the
periods shown, except for the omission of footnotes and customary year-end
adjustments, which adjustments will not be material, individually or in the
aggregate. The books and records of the Company are true and correct in all
material respects.

      3.7 LIABILITIES. Other than as set forth on Schedule 3.7, since the
Balance Sheet Date, the Company has incurred no material debts, liabilities or
obligations, including contingent liabilities, except any incurred in the
ordinary course of business that are not individually or in the aggregate
material.

      3.8 MATERIAL EVENTS. Since the Balance Sheet Date and other than the
Transaction Documents or as set forth on Schedule 3.3 and Schedule 3.8, (i)
there has been no change in the business, assets, liabilities, condition
(financial or otherwise), operations or prospects of the Company except for
changes in the ordinary course of business that, in the aggregate, have not or
would not reasonably be expected to have a Material Adverse Effect, and (ii) the
Company has not (A) issued any stock, bond or other corporate security, (B)
borrowed any amount, (C) discharged

                                       4
<PAGE>

or satisfied any lien or encumbrance or incurred or paid any obligation or
liability (absolute, accrued or contingent), other than current liabilities
shown on the Financial Statements, (D) declared or made any payment or
distribution to shareholders or purchased or redeemed any shares of its capital
stock or other securities, (E) mortgaged, pledged or subjected to lien any of
its assets, tangible or intangible, other than liens of current real property
taxes not yet due and payable, (F) sold, assigned or transferred any of its
material tangible assets, or canceled any material debt or claim, (G) sold,
assigned, transferred or granted any license with respect to any patent,
trademark, trade name, service mark, copyright, trade secret or other intangible
asset, (H) suffered any material loss of property or waived any right of
substantial value, whether or not in the ordinary course of business, or (I)
made any material change in the manner of business or operations of the Company.

      3.9 LITIGATION. There is no litigation or governmental proceeding or
investigation pending or, to the Knowledge of the Company, threatened (i)
against the Company or affecting any of the Company's properties or assets, or
(ii) to the Knowledge of the Company, against any director, officer, key
employee or shareholder of the Company in his or her capacity as such that would
reasonably be expected to have a Material Adverse Effect .

      3.10 COMPLIANCE WITH LAWS AND OTHER INSTRUMENTS. The Company is in
compliance with all of the provisions of its Articles of Incorporation and
By-Laws and, in all material respects, with each judgment, decree, judicial
order, statute, and regulation by which it is bound or to which it or any of its
properties is subject, and is otherwise in compliance in all material respects
with the provisions of each mortgage, indenture, lease, license, other agreement
or instrument to which it is party or to which any of its material assets is
subject. The Company has never materially violated, and is presently in all
material respects in compliance with, all federal, state, and local
environmental and health and safety laws, rules, regulations, ordinances, and
by-laws applicable to its business and properties. To the Knowledge of the
Company, there is no contamination of any real property leased or operated by
the Company that could reasonably be expected to subject the Company to
liability under any environmental laws or regulations. Neither the Company nor
any director, officer, key employee or shareholder of the Company in his or her
capacity as such, is, to the Knowledge of the Company, in default with respect
to any order, writ, injunction, decree, ruling or decision of any court,
commission, board or other government agency, which default would reasonably be
expected to have a Material Adverse Effect. Subject to receipt of the
shareholder approvals contemplated by the "Effective Date" provisions of the
Alliance Agreement, neither the execution, delivery or performance of the
Transaction Documents, including, without limitation, the offer, issuance or
delivery of the Preferred Shares and the Conversion Shares, requires the consent
or approval of any Person or, with or without the giving of notice or passage of
time, or both, will violate, or result in any breach of, or constitute a default
under, or result in the imposition of any encumbrance upon any asset of the
Company pursuant to any provision of its Articles of Incorporation or By-Laws,
or of any statute, rule or regulation, contract, lease, judgment, order, decree
or other document or instrument (other than the Transaction Documents) by which
the Company is bound or to which the Company or any of its material properties
are subject, or will cause the Company to lose the benefit of any right or
privilege it presently enjoys.

                                       5
<PAGE>

      3.11 TAXES. The Company has filed all tax returns, reports and forms
(including statements of estimated taxes owed) required to be filed within the
applicable periods for such filings (taking into account available extensions)
and has paid all taxes required to be paid, and has established adequate
reserves (net of estimated tax payments already made) for the payment of all
taxes payable in respect to the period subsequent to the last periods covered by
such returns. All such tax returns, reports and forms are true, correct and
complete in all material respects. No deficiencies for any tax are currently
assessed against the Company, no tax returns of the Company have ever been
audited, and, to the Knowledge of the Company, there is no such audit pending or
contemplated. Proper and adequate amounts have been withheld by the Company from
its employees and other persons for all periods in compliance in all material
respects with the tax, social security and unemployment and other withholding
provisions of all federal, state, local and foreign laws. There is no tax lien,
whether imposed by any federal, state or local taxing authority, outstanding
against the assets, properties or business of the Company. The Company is not a
party to any agreement, arrangement or practice for the sharing of taxes or
obligated to indemnify any other party for taxes. For the purposes of this
Agreement, the term "tax" shall include all federal, state, local and foreign
taxes, including income, franchise, property, sales, use, gross receipts,
excise, withholding, payroll and employment taxes and other similar assessments
of any kind whatsoever, including all interest, penalties and additions imposed
with respect to such amounts.

      3.12 REAL PROPERTY. The Company owns no real property. Schedule 3.12 of
the Disclosure Schedule sets forth the addresses and uses of all real property
that the Company leases or subleases and any lien or encumbrance on any of the
Company's leasehold interest therein, specifying the name of the lessor or
sublessor, as the case may be, and the lease term. The Company enjoys peaceful
and undisturbed possession under all leases under which it is operating, and all
such leases are valid and subsisting and in full force and effect. There are no
defaults by the Company or, to the Knowledge of the Company, by any other party
thereto, under any of the leases or other instruments required to be listed on
Schedule 3.12 of the Disclosure Schedule that might curtail in any material
respect the present use of the Company's property subject to the respective
lease or instrument. There is no material violation by the Company of any law,
regulation or ordinance (including, without limitation, laws, regulations or
ordinances relating to zoning, environmental, city planning or similar matters)
relating to any real property leased or subleased by the Company.

      3.13 PERSONAL PROPERTY. The Company owns free and clear of any liens or
encumbrances all of the personal property reflected as owned by the Company in
the balance sheet contained in the Unaudited Financial Statement (subject only
to any dispositions of current assets in the ordinary course of business since
such balance sheet date), and all other material items of personal property
acquired by the Company through the date hereof.

      3.14 INTELLECTUAL PROPERTY.

            (a) Set forth on Schedule 3.14 of the Disclosure Schedule is a list
of all patents, patent rights, patent applications, trademarks, trademark
applications, service marks, service mark applications, trade names, material
copyrights, and Internet domain names that are owned by the Company or of which
the Company is a licensee or in which the Company has any other right.

                                       6
<PAGE>

            (b) The Company owns or possesses adequate licenses or other legally
binding rights to use all patents, patent rights, patent applications,
trademarks, trademark applications, service marks, service mark applications,
trade names, copyrights, Internet domain names, manufacturing processes,
formulae, trade secrets and know how (collectively, "Intellectual Property")
necessary to the conduct of its business as presently conducted and as it is
presently intended to be conducted.

            (c) To the Company's Knowledge, the present and presently intended
operations of the Company do not infringe upon or conflict with the rights of
any other Person with respect to any Intellectual Property, and no claim is
pending or, to the Knowledge of the Company, threatened to the effect that any
Intellectual Property owned or licensed by the Company, or that the Company
otherwise has the right to use, is invalid or unenforceable by the Company or
infringes upon the rights of any third party.

            (d) The Company is not making unlawful use of any confidential
information or trade secrets of any past or present employee of or consultant to
the Company. No current or former shareholder, employee, officer or director of
or consultant to the Company has (directly or indirectly) any right, title or
interest in any of the Intellectual Property described in clause (b) other than
any such interest that such Person may enjoy in his or its capacity as a
shareholder of the Company.

      3.15 AGREEMENTS OF DIRECTORS, OFFICERS AND EMPLOYEES. To the Knowledge of
the Company, no director, officer or employee of or consultant to the Company is
in violation of any terms of any employment contract, non-competition agreement,
non-disclosure agreement, patent disclosure or assignment agreement or other
contract or agreement containing restrictive covenants relating to the right of
any such director, officer, employee or consultant to be employed or engaged by
the Company because of the nature of the business conducted or proposed to be
conducted by the Company, or relating to the use of trade secrets or proprietary
information of others.

      3.16 CONTRACTS AND COMMITMENTS. Schedule 3.16 of the Disclosure Schedule
contains a list of all Agreements (as defined below), to which the Company is a
party or by which it or any of its properties are bound. Other than the
agreements listed on Schedule 3.16 of the Disclosure Schedule, the Company does
not have any (A) material agreements relating to the borrowing of money; (B)
licenses to use, modify, or sell any Intellectual Property (provided that a
license to use (only) off-the-shelf software need not be listed unless it is a
site license); (C) material distributor or sales representative agreements; (D)
material agreements with officers, directors, employees or shareholders of the
Company or persons or organizations related to or affiliated with any such
persons; (E) material leases of real or personal property; or (F) material
agreements relating to product or service development. All the agreements and
other instruments required to be listed on Schedule 3.16 of the Disclosure
Schedule are valid, binding and in full force and effect against the Company
and, to the Knowledge of the Company, against the other parties thereto. The
Company is not in default under any contract or agreement nor any other
agreement or instrument required to be disclosed by this section, and to the
Knowledge of the Company, there is no state of facts that, upon notice or with
lapse of time or both, would reasonably be expected to constitute a default
under any such agreement, except in all cases for purposes of this sentence for
such defaults as would not reasonably be expected to have a Material Adverse
Effect. For purposes of this Section

                                       7
<PAGE>

3.16, the term "Agreement" shall mean an agreement, contract obligation or
commitment that (i) requires future expenditures by the Company in excess of
$100,000 or can reasonably be expected to result in payments to the Company in
excess of $100,000 or (ii) related to the sale, transfer or license of any of
the Company's intellectual property (other than licenses entered into in the
ordinary course of business).

      3.17 SECURITIES ACT. In partial reliance on the representations of Takeda
set forth in Article 4, the Company has complied with all applicable United
States federal or state securities laws in connection with the issuance of the
Preferred Shares. Neither the Company nor anyone acting on its behalf has
offered the Preferred Shares or similar securities, or solicited any offers to
purchase any of such securities, so as to require registration of the issuance
of the Preferred Shares under the Securities Act of 1933, as amended (the
"Securities Act") or any state securities law.

      3.18 INSURANCE COVERAGE. The Company currently maintains property and
casualty insurance, general liability insurance, and such other insurance in
such amounts and covering such risks as are usually and customarily carried by
persons engaged in the business conducted by the Company and are reasonably
sufficient to prevent the Company from becoming a co-insurer with respect to the
risks covered by such insurance. There are currently no claims pending against
the Company under any insurance policies currently in effect and covering the
property, business or employees of the Company, and all premiums due and payable
with respect to the policies maintained by the Company have been paid to date.
The Company recently submitted notice of a possible insurance claim in
connection with a non-moving collision by a third party with a car rented by one
of the Company's employees (estimated damage is US $2,500.00 or less.).

      3.19 EMPLOYEE MATTERS. Schedule 3.19 of the Disclosure Schedule describes
all material employment, consulting and severance agreements and arrangements,
all deferred compensation, pension or retirement agreements or arrangements, all
bonus, incentive or profit-sharing plans or arrangements, and all labor or
collective bargaining agreements, written or oral, that the Company has in
effect. The Company and each such plan, agreement, or arrangement is in
compliance in all material respects with all applicable laws and regulations
relating to such plans, agreements, and arrangements, as well as to labor,
employment, fair employment practices, terms and conditions of employment, and
wages and hours. The Company is in compliance in all material respects with the
terms of all such plans, programs, agreements and arrangements. To the Knowledge
of the Company, none of the officers or other key employees of the Company
presently intends to terminate his or her employment. The Company does not have
any Employee Benefit Plans as defined in the Employee Retirement Income Security
Act of 1974. The Company is not bound by or subject to (and none of its assets
or properties is bound by or subject to) any written or oral, express or
implied, contract, commitment or arrangement with any labor union, and no labor
union has requested or, to the Company's Knowledge, has sought to represent any
of the employees, representatives or agents of the Company. There is no strike
or other labor dispute involving the Company pending, or to the Company's
Knowledge, threatened, that reasonably could be expected to have a Material
Adverse Effect, nor is the Company aware of any labor organization activity
involving its employees.

                                       8
<PAGE>

      3.20 NO BROKERS OR FINDERS. No person has or will have, as a result of the
transactions contemplated by this Agreement, any right, interest or claim
against or upon the Company or Takeda for any commission, fee or other
compensation as a finder or broker because of any act or omission by the
Company.

      3.21 TRANSACTIONS WITH AFFILIATES. Except as disclosed in the Financial
Statements, or on Schedule 3.16, there are no loans, leases or other continuing
transactions between the Company, on the one hand, and any officer or director
of the Company or any person owning five percent (5%) or more of any class or
classes of equity security of the Company or any family member or affiliate of
any such officer, director or shareholder, on the other hand. Except as
disclosed in the Financial Statements, or on Schedule 3.16, none of such persons
has (a) any direct or indirect ownership interest in any firm or corporation
with which the Company has any business relationship, or that competes with the
Company (other than a passive investment in a publicly-traded company), or (b)
any direct or indirect interest in any material contract of the Company.

      3.22 ASSUMPTIONS, GUARANTEES, ETC. OF INDEBTEDNESS OF OTHER PERSONS. The
Company has not assumed, guaranteed, endorsed or otherwise become directly or
contingently liable on or for any indebtedness of any other Person, except
guarantees by endorsement of negotiable instruments for deposit or collection or
similar transactions in the ordinary course of business.

      3.23 BOOKS AND RECORDS. The minute books of the Company, as furnished to
counsel for Takeda, contain complete and accurate records of all corporate
actions taken at meetings of its shareholders and its Board of Directors and
committees thereof, except for minor portions of such minutes as were redacted
for competitive reasons and marked as redacted in the copies provided to counsel
for Takeda. The stock ledger of the Company is complete and reflects all
issuances, transfers, repurchases and cancellations of shares of capital stock
of the Company.

      3.24 DISCLOSURE. The Company has provided Takeda and/or Takeda's legal,
accounting, financial or other advisors with access to all the information that
Takeda has requested for deciding whether to acquire the Preferred Shares and
all material information that the Company believes is reasonably necessary to
enable Takeda to make such decision. Neither this Agreement, any Schedule or
Exhibit to this Agreement, the Financial Statements, nor the representations and
warranties made in this Agreement and the Alliance Agreement, to the extent the
foregoing pertain to statements by the Company, contains any untrue statement of
material fact or, when taken as a whole, omits any material fact necessary to
make the statements contained herein or therein not misleading. As of the date
of execution of this Agreement, the Company has, to its Knowledge, provided
Takeda and/or Takeda's legal, accounting, financial or other advisors with the
opportunity to review all Material Data (as defined in the Alliance Agreement)
in the Company's possession, and has not concealed from Takeda any Material
Data. The Company has provided Takeda with a summary of certain risk factors
relating to the Company, a copy of which summary is included as Schedule 3.24
hereto.

                                       9
<PAGE>

      ARTICLE 4.REPRESENTATIONS AND WARRANTIES OF TAKEDA.

            Takeda hereby represents and warrants to the Company as follows:

            4.1 REQUISITE POWER AND AUTHORITY. Takeda has all necessary power
      and authority under all applicable provisions of law to execute and
      deliver this Agreement and the other Transaction Documents and to carry
      out its obligations hereunder and thereunder. All action on Takeda's part
      required for the lawful execution and delivery of the Transaction
      Documents has been or will be effectively taken before the Closing. Upon
      its execution and delivery, each of the Transaction Documents will be the
      valid and binding obligation of Takeda, enforceable in accordance with its
      terms, except as limited by applicable bankruptcy, insolvency,
      reorganization, moratorium or other laws of general application affecting
      enforcement of creditors' rights and general principles of equity that
      restrict the availability of equitable remedies.

            4.2 SECURITIES LAW REPRESENTATIONS AND WARRANTIES. Takeda has been
      advised that the Preferred Shares are not being registered under the
      Securities Act of 1933, as amended (the "Securities Act"), or applicable
      state securities laws, but are being offered and sold pursuant to
      exemptions from such laws. Takeda acknowledges that the Company is relying
      in part upon the following representations and warranties of Takeda for
      the purpose of qualifying the offer and sale of the Preferred Shares for
      applicable exemptions from registration or qualification pursuant to
      federal or state securities laws, rules and regulations.

                  (i) Purchase Entirely for Own Account. Takeda is acquiring the
            Preferred Shares for its own account and not with a view to, or for
            sale in connection with, any distribution thereof, nor with the
            intention of distributing or reselling the same.

                  (ii) Accredited Investor. Takeda is an "Accredited Investor"
            as such term is defined in Rule 501 of Regulation D, as promulgated
            under the Securities Act.

                  (iii) Residency. Takeda represents that it is a bona fide
            resident of, and/or is domiciled in, Osaka, Japan.

                  (iv) Foreign Investors. Because Takeda is not a United States
            person (as defined by Section 7701(a)(30) of the Internal Revenue
            Code of 1986, as amended), Takeda represents that it has satisfied
            itself as to the full observance of the laws of its jurisdiction in
            connection with the purchase of the Preferred Shares or execution of
            this Agreement, including (i) legal requirements within its
            jurisdiction for the purchase of the Preferred Shares, (ii) any
            foreign exchange restrictions applicable to such purchase or
            acquisition, (iii) any government or other consents that may need to
            be obtained, and (iv) the income tax and other tax consequences, if
            any, that may be relevant to the purchase, holding, redemption, sale
            or transfer of the Preferred Shares. Takeda's purchase of the
            Preferred Shares will not violate any applicable securities or other
            laws of Takeda's jurisdiction.

            4.3 NO BROKERS OR FINDERS. No person has or will have, as a result
      of the transactions contemplated by this Agreement, any right, interest or
      claim against or upon the Company for any commission, fee or other
      compensation as a finder or broker because of any act or omission by
      Takeda.

                                       10
<PAGE>

      ARTICLE 5. CONDITIONS TO CLOSING.

            5.1 CONDITIONS TO TAKEDA'S OBLIGATIONS. Takeda's obligation to
      purchase the Preferred Shares at the Closing is subject to the
      satisfaction, at or before the Closing, of the following conditions, any
      of which may be waived by Takeda:

                  (a) REPRESENTATIONS AND WARRANTIES; PERFORMANCE OF
      OBLIGATIONS. The representations and warranties made by the Company in
      Section 3 hereof and in the Alliance Agreement shall be true and correct
      in all material respects as of the Closing Date as if made on and as of
      such date (except to the extent such representations and warranties speak
      as of a particular date, in which case they shall have been correct as of
      such date); the Company shall have performed and complied with all
      agreements and conditions contained in this Agreement and in the Alliance
      Agreement required to be performed or complied with by it before or at the
      Closing; and the Company shall have delivered to Takeda a certificate
      signed by its Chief Executive Officer to that effect dated as of the
      Closing Date.

                  (b) LEGAL INVESTMENT. On the Closing Date, the sale and
      issuance of the Preferred Shares and the proposed issuance of the
      Conversion Shares shall be legally permitted by all laws and regulations
      to which Takeda and the Company are subject.

                  (c) GOOD STANDING CERTIFICATE. The Company shall have
      delivered to counsel for Takeda, as of the most recent practicable date, a
      certificate of the Secretary of the State of Texas (the "Secretary of
      State") as to the Company's corporate good standing.

                  (d) LEGAL OPINION. Takeda shall have received from Akin Gump
      Strauss Hauer & Feld LLP, counsel to the Company, an opinion reasonably
      satisfactory to counsel for Takeda, addressed to Takeda and dated as of
      the Closing Date.

                  (e) CONSENTS, PERMITS, AND WAIVERS. The Company shall have
      made all filings with governmental agencies and obtained any and all
      approvals, consents, permits and waivers of any Person necessary or
      appropriate for consummation of the transactions contemplated by the
      Transaction Documents (except for such as may be properly made or obtained
      after the Closing).

                  (f) REGISTRATION RIGHTS AGREEMENT. The Registration Rights
      Agreement shall have been executed and delivered by the Company.

                  (g) CERTIFICATES AND DOCUMENTS. The Company shall have
      delivered to counsel for Takeda: (i) a copy of the Articles of
      Incorporation, certified by the Secretary of the State; and (ii) a
      certificate of the Secretary or Assistant Secretary of the Company dated
      as of the Closing Date as to (A) the incumbency of officers of the Company
      executing the Transaction Documents and all other documents executed and
      delivered in connection herewith, (B) the By-laws of the Company as in
      effect on and as of the Closing Date, and (C) the resolutions of the Board
      of Directors and, to the extent applicable, shareholders of the Company
      authorizing and approving the Transaction Documents and all of the
      transactions contemplated hereby and thereby.

                                       11
<PAGE>

                  (h) OTHER MATTERS. All corporate and other proceedings by the
      Company in connection with the transactions contemplated at the Closing by
      this Agreement, and all documents and instruments provided by the Company
      incident to such transactions, shall be reasonably satisfactory in
      substance and form to Takeda and its counsel, and Takeda and its counsel
      shall have received all such counterpart originals or certified or other
      copies of such documents as they may have requested.

            5.2 CONDITIONS TO OBLIGATIONS OF THE COMPANY. The Company's
      obligation to issue the Preferred Shares at the Closing is subject to the
      satisfaction, at or before the Closing, of the following conditions, any
      of which may be waived by the Company:

                  (a) REPRESENTATIONS AND WARRANTIES. The representations and
      warranties made by Takeda in Section 4 hereof and in the Alliance
      Agreementshall be true and correct in all material respects as of the
      Closing Date as if made on and as of such date (except to the extent such
      representations and warranties speak as of a particular date, in which
      case they shall have been correct as of such date).

                  (b) PERFORMANCE. Takeda shall have performed and complied with
      all agreements contained herein and in the Alliance Agreement required to
      be performed or complied with by it prior to or at the Closing Date,
      including, to the extent required, the filing of the HSR Report as
      described in the Alliance Agreement.

                  (c) LEGAL INVESTMENT. On the Closing Date, the sale and
      issuance of the Preferred Shares and the proposed issuance of the
      Conversion Shares shall be legally permitted by all laws and regulations
      to which Takeda and the Company are subject.

                  (d) OTHER MATTERS. All corporate and other proceedings by
Takeda in connection with the transactions contemplated at the Closing by this
Agreement, and all documents and instruments provided by Takeda incident to such
transactions, shall be reasonably satisfactory in substance and form to the
Company and its counsel, and the Company and its counsel shall have received all
such counterpart originals or certified or other copies of such documents as
they may have requested.

      ARTICLE 6. MISCELLANEOUS.

            6.1 LEGENDS. It is understood that the certificates evidencing the
      Preferred Shares will bear a legend substantially to the effect that:

                  (a) "THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
      SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED,
      ASSIGNED OR HYPOTHECATED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION
      STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES OR (B) SUCH SALE IS
      EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH
      ACT; PROVIDED, HOWEVER, THAT THE SECURITIES MAY BE TRANSFERRED, WITHOUT
      RESTRICTION, TO A WHOLLY-OWNED SUBSIDIARY OF, OR TO ANY ENTITY WHICH OWNS
      A CONTROLLING INTEREST IN, OR IS UNDER COMMON CONTROL WITH, THE HOLDER OF
      THE SECURITIES;" and

                                       12
<PAGE>

                  (b) Any legend required by the blue sky laws of any state to
      the extent such laws are applicable to the shares represented by the
      certificate so legended.

            6.2 GOVERNING LAW. This Agreement shall be construed and enforced in
      accordance with the internal laws of New York, United States of America,
      without reference to choice of law.

            6.3 CERTIFICATE STATEMENTS. All statements as to factual matters
      contained in any certificate or other instrument delivered by or on behalf
      of the Company as part of the Closing shall be deemed to be
      representations and warranties by the Company hereunder as of the date of
      such certificate or instrument.

            6.4 SUCCESSORS AND ASSIGNS. Except as otherwise expressly provided
      herein, the provisions hereof shall inure to the benefit of, and be
      binding upon, the successors, assigns, heirs, executors and administrators
      of the parties hereto and shall inure to the benefit of and be enforceable
      by each person who shall be a holder of the Preferred Shares or the
      Conversion Shares (other than any that have been sold in a public sale)
      from time to time.

            6.5 ENTIRE AGREEMENT. This Agreement, including the Exhibits and
      Schedules hereto, the other Transaction Documents, and the other documents
      delivered pursuant hereto and thereto, constitute the full and entire
      understanding and agreement between the parties with regard to the subject
      matter hereof and thereof, superseding all prior agreements and
      understandings, and no party shall be liable or bound to any other in any
      manner by any representations, warranties, covenants and agreements except
      as specifically set forth herein and therein.

            6.6 SEVERABILITY. In case any provision of this Agreement shall be
      invalid, illegal or unenforceable, the validity, legality and
      enforceability of the remaining provisions shall not in any way be
      affected or impaired thereby.

            6.7 AMENDMENT AND WAIVER. This Agreement may be amended or modified,
      and any provision hereof may be waived, only upon the written consent of
      both the Company and Takeda.

            6.8 NOTICES. All notices, reports, and audit requests with respect
      to this Agreement shall be made in writing and will be given by certified
      mail, return receipt requested, by recognized international courier
      service or by personal delivery properly addressed to the party for whom
      it is intended as follows:

            If to Takeda:

                  General Manager, Divisions of Americas
                  Takeda Pharmaceutical Company Limited
                  1-1, Doshomachi 4-chome, Chuo-Ku, Osaka, 540-8645, Japan

                                       13
<PAGE>

            with a copy to:

                  General Manager, Legal Department
                  Takeda Pharmaceutical Company Limited
                  1-1, Doshomachi 4-chome, Chuo-Ku, Osaka, 540-8645, Japan

            If to the Company:

                  Chief Executive Officer
                  BioNumerik Pharmaceuticals, Inc.
                  8122 Datapoint Drive, Suite 1250
                  San Antonio, TX 78229

            All notices are deemed effective on the date of receipt or, if
      delivery is not accepted, five (5) days after placement with a post office
      for delivery by certified mail, return receipt requested as described
      above and five (5) days after placement with a recognized international
      courier service for delivery as described above.

            6.9 TITLES AND SUBTITLES. The titles of the sections and subsections
      of the Agreement are for convenience of reference only and are not to be
      considered in construing this Agreement.

            6.10 COUNTERPARTS. This Agreement may be executed in any number of
      counterparts, each of which shall be an original, but all of which
      together shall constitute one instrument.

            IN WITNESS WHEREOF, the parties hereto have executed this
      Convertible Preferred Stock Purchase Agreement as of the date set forth in
      the first paragraph hereof.

      BIONUMERIK PHARMACEUTICALS, INC.

      By:   /S/ FREDERICK H. HAUSHEER
            ------------------------------------
      Printed Name:  Frederick H. Hausheer, M.D.
      Title:         Chairman, CEO and President

      TAKEDA PHARMACEUTICAL COMPANY LIMITED

      By:   /S/ SABURO HAMANAKA
            ------------------------------------
      Printed Name:  Saburo Hamanaka
      Title:         Corporate Officer
                     General Manager, Division of Americas
                                       14<PAGE>

                                                                    EXHIBIT 10.1

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                          STRATEGIC ALLIANCE AGREEMENT

                                     BETWEEN

                        BIONUMERIK PHARMACEUTICALS, INC.

                                       AND

                         ASTA MEDICA AKTIENGESELLSCHAFT

                              18TH OF JANUARY, 2001
<PAGE>
                                TABLE OF CONTENTS
<TABLE>
<S>                                                                                                        <C>
RECITALS ................................................................................................      1

1. DEFINITIONS ..........................................................................................      1
   1.1      Affiliate(s).................................................................................      2
   1.2      Alliance Steering Committee..................................................................      2
   1.3      ASTA Medica Improvements.....................................................................      2
   1.4      ASTA Medica Know-How.........................................................................      2
   1.5      ASTA Medica Patent Rights....................................................................      2
   1.6      BioNumerik Improvements......................................................................      2
   1.7      BioNumerik Know-How..........................................................................      3
   1.8      BioNumerik Patent Rights.....................................................................      3
   1.9      BNP7787......................................................................................      3
   1.10     Budget.......................................................................................      3
   1.11     Competitor...................................................................................      4
   1.12     Confidential Information.....................................................................      4
   1.13     Costs........................................................................................      4
   1.14     Development Plan.............................................................................      4
   1.15     Fiscal Year..................................................................................      4
   1.16     Government Regulatory Approvals..............................................................      4
   1.17     Gross Profits................................................................................      4
   1.18     Gross Sales..................................................................................      4
   1.19     Improvements.................................................................................      5
   1.20     Know-How.....................................................................................      5
   1.21     Parties......................................................................................      5
   1.22     Patents......................................................................................      5
   1.23     Patent Rights................................................................................      5
   1.24     Product(s)...................................................................................      5
   1.25     Product Trademark............................................................................      6
   1.26     Supply Agreement.............................................................................      6
   1.27     Territory....................................................................................      6
   1.28     Trademarks...................................................................................      6
2. GRANT OF RIGHTS ......................................................................................      6
   2.1      Research and Development License.............................................................      6
   2.2      License to Market, Sell and Distribute.......................................................      6
   2.3      Sublicenses..................................................................................      7
   2.4      Canada Right of First Offer..................................................................      7
   2.5      Retention of Rights..........................................................................      7
   2.6      Provision of Know-How........................................................................      8
   2.7      Distribution.................................................................................      8
   3.       MANAGEMENT OF RELATIONSHIP...................................................................      8
   3.1      Steering Committee...........................................................................      8
   3.2      Project Team.................................................................................      9
   3.3      Additional Teams and Assistance..............................................................     10
   3.4      Cooperation..................................................................................     10
   3.5      Voting and Dispute Resolution................................................................     10
   3.6      Costs of Maintenance and Operation...........................................................     10
   4.       DEVELOPMENT PLAN AND COSTS...................................................................     11
   4.1      Development Costs............................................................................     11
   4.2      Government Approvals and Clinical Trials.....................................................     11
</TABLE>

                                        i
<PAGE>
<TABLE>
<S>                                                                                                        <C>
   4.3      Development Plan and Budget..................................................................     12
   4.4      Promotional Materials involving BioNumerik and Labeling......................................     13
5. LICENSE FEES AND ROYALTIES ...........................................................................     13
   5.1      License Fees.................................................................................     13
   5.2      Royalties....................................................................................     13
   5.3      Expiration of Royalty Obligations............................................................     14
   5.4      Inclusion of Sublicense Fees.................................................................     14
   5.5      Sales Forecast and Payment...................................................................     14
   5.6      Forecast Adjustment..........................................................................     15
 6.INFORMATION SHARING ..................................................................................     15
   6.1      Sharing of Information.......................................................................     15
   6.2      BioNumerik Information.......................................................................     16
   6.3      Additional Information Sharing...............................................................     16
7. MANUFACTURING ........................................................................................     17
   7.1      Manufacturing Rights.........................................................................     17
   7.2      Non-Exclusive Manufacturing Option for Territory.............................................     17
   7.3      Pre-Commercial Manufacturing.................................................................     18
   7.4      Commercial Supply Agreement..................................................................     18
   7.5      No Infringing Manufacture or Supply..........................................................     19
8. DILIGENCE ............................................................................................     19
   8.1      General Diligence Efforts....................................................................     19
   8.2      Target Development and Commercialization Plan................................................     19
 9.PATENT MATTERS .......................................................................................     20
   9.1      BioNumerik Patent Maintenance................................................................     20
   9.2      ASTA Medica Patent Maintenance and Assistance................................................     21
   9.3      BioNumerik Patent Representations............................................................     21
   9.4      ASTA Medica Patent Representations...........................................................     21
   9.5      Enforcement of Patents and Proprietary Rights................................................     22
10.TRADEMARKS AND TRADEMARK RIGHTS ......................................................................     23
   10.1     Registration, Maintenance and Ownership......................................................     23
11.IMPROVEMENTS .........................................................................................     24
   11.1     BioNumerik Improvements Included.............................................................     24
   11.2     ASTA Medica Improvement Grantbacks...........................................................     25
   11.3     Joint Improvements...........................................................................     25
   11.4     Sublicenses..................................................................................     25
12.CONFIDENTIALITY ......................................................................................     26
   12.1     Confidential and Proprietary Information.....................................................     26
   12.2     Matters not Included as Confidential Information.............................................     26
   12.3     Survival of Confidentiality..................................................................     27
13.PAYMENTS, RECORDS AND ACCOUNTING .....................................................................     27
   13.1     Means of Payment.............................................................................     27
   13.2     Currency.....................................................................................     27
   13.3     Access to Records............................................................................     28
   13.4     Taxes and Required Withholdings..............................................................     28
14.DURATION AND TERMINATION OF AGREEMENT ................................................................     28
   14.1     Duration.....................................................................................     28
   14.2     Termination..................................................................................     29
   14.3     Effect of Expiration or Termination..........................................................     31
   14.4     Termination for BioNumerik's Breach, Change in Control or Bankruptcy.........................     31
   14.5     Termination for ASTA Medica's Breach, Change in Control or Bankruptcy........................     32
</TABLE>

                                       ii
<PAGE>

<TABLE>
<S>                                                                                                        <C>
   14.6     Termination Due to Cessation of Regulatory Authorization or Lack of Patent Coverage..........     32
   14.7     Sale of Inventory............................................................................     33
   14.8     Country Specific Termination of Rights.......................................................     33
15.BIONUMERIK REPRESENTATIONS & WARRANTIES ..............................................................     33
   15.1     Due Organization and Authority...............................................................     33
   15.2     Safety of Product(s).........................................................................     34
   15.3     Warranties on Quality of the Know-How........................................................     34
   15.4     Governmental Agencies and Product Documentation..............................................     34
   15.5     Circumstances and Acts.......................................................................     34
16.ASTA MEDICA REPRESENTATIONS AND WARRANTIES ...........................................................     35
   16.1     Due Organization and Authority...............................................................     35
   16.2     Right to Accept License; Due Diligence.......................................................     35
   16.3     Governmental Agencies........................................................................     35
   16.4     Circumstances and Acts.......................................................................     35
17.INDEMNIFICATION ......................................................................................     35
   17.1     Indemnification by BioNumerik................................................................     35
   17.2     Indemnification by ASTA Medica...............................................................     36
   17.3     Mechanics....................................................................................     36
   17.4     Insurance Coverage...........................................................................     36
18.RELATION OF THE PARTIES ..............................................................................     37
19.ASSIGNMENTS ..........................................................................................     37
   19.1     Assignment Restrictions......................................................................     37
   19.2     Sale of Business.............................................................................     38
   19.3     Assignments to Competitors
   19.4     Assignment to Affiliates.....................................................................     38
20.MISCELLANEOUS ........................................................................................     39
   20.1     Regulatory Communications....................................................................     39
   20.2     Adverse Effects..............................................................................     39
   20.3     Market Analysis and Marketing Reports........................................................     39
   20.4     Notice/Reports...............................................................................     40
   20.5      Severability................................................................................     40
   20.6     Counterparts.................................................................................     40
   20.7     Warranty Disclaimer..........................................................................     41
   20.8     Force Majeure................................................................................     41
   20.9     Arbitration..................................................................................     41
   20.10    Export Controls..............................................................................     42
   20.11    Construction / Jurisdiction / Official Language..............................................     42
21.USE OF NAMES .........................................................................................     42
22.ENTIRE AGREEMENT .....................................................................................     43
23.CAPTIONS .............................................................................................     43
</TABLE>

                                      iii

<PAGE>
                          STRATEGIC ALLIANCE AGREEMENT

         THIS AGREEMENT ("Agreement") is made and entered into effective as of
the 18th day of January, 2001, between ASTA Medica Aktiengesellschaft, a German
corporation with its office located at An der Pikardie 10, D-01277 Dresden,
Germany (hereinafter referred to as "ASTA Medica") and BioNumerik
Pharmaceuticals, Inc., a Texas corporation, with its office located at 8122
Datapoint Drive, Suite 1250, San Antonio, Texas 78229, U.S.A. (hereinafter
referred to as "BioNumerik").

                                    RECITALS:

         WHEREAS, BioNumerik is the owner of certain inventions, trade secrets,
know-how and rights relating to a certain medicinal toxicity protecting and
mitigating agent and related compounds denoted as "BNP7787", and has been issued
and has applied for certain patent and trademark rights with respect to BNP7787
and has developed BNP7787 for the treatment and mitigation of various clinically
important toxicities.

         WHEREAS, BioNumerik and ASTA Medica wish to further the development of
BNP7787 for the prevention, treatment and mitigation of various medical
treatment-associated toxicities that are associated with drug administration and
other treatments in designated territories of the world.

         NOW, THEREFORE, in consideration of the financial terms set forth
herein and of the other terms, conditions and agreements contained herein, and
for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, BioNumerik and ASTA Medica hereby agree as follows:

         1. DEFINITIONS. When used in this Agreement, each of the following
defined terms shall have the meanings set forth in this Section. There are other
terms defined in this Agreement parenthetically, and such terms shall have the
meanings apparent from the context in which such terms are parenthetically
defined.

                  1.1 "Affiliate(s)" means, with respect to each Party, any
organization, company, firm, or other entity that controls, is controlled by, or
is under common control with said Party. A company shall be deemed to have
control of another if it owns directly or indirectly a majority of the voting
shares of or is

                                       1
<PAGE>
entitled directly or indirectly to appoint a majority of the directors or other
managing body of the other company.

                  1.2 "Alliance Steering Committee" means the Alliance Steering
Committee described in Section 3 hereof.

                  1.3 "ASTA Medica Improvements" means any and all inventions,
developments, discoveries, and improvements useful in the development,
manufacture or sale of the Product(s), including, without limitation, formulae,
compounds, specifications, designs, chemical and physical data, clinical data,
information concerning synthesis, processes, formulations, applications,
toxicity, operations, regulatory affairs and marketing, that are developed by or
for ASTA Medica subsequent to the date of the Confidentiality Agreement between
BioNumerik and ASTA Medica dated as of December 12, 1998 (the "BioNumerik
Confidentiality Agreement") and during the term of this Agreement, subject in
all cases to any restrictions that may exist on the ability of ASTA Medica to
license such inventions, developments, discoveries or improvements to BioNumerik
in accordance with Sections 11 and 14 of this Agreement.

                  1.4 "ASTA Medica Know-How" means all data and information
owned by ASTA Medica and useful in the development, manufacture or sale of the
Product(s), including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, information concerning synthesis,
processes, formulations, manufacture of the Active Pharmaceutical Ingredient
(API) for the Product(s), applications, administration to patients, clinical
protocols, toxicity, operations, regulatory affairs and marketing, that have
been developed by or for ASTA Medica on or before the date of the BioNumerik
Confidentiality Agreement, subject in all cases to any restrictions that may
exist on the ability of ASTA Medica to use and license such know-how in
accordance with the terms of this Agreement.

                  1.5 "ASTA Medica Patent Rights" means all patents or patent
applications (excluding the BioNumerik Patent Rights) owned or controlled by
ASTA Medica relating to ASTA Medica Know-How, ASTA Medica Improvements or other
matters that are useful in the development, manufacture or sale of the
Product(s) or that bear some tangible relationship to the Product(s).

                  1.6 "BioNumerik Improvements" means any and all inventions,
developments, discoveries and improvements useful in the development,
manufacture or sale of the Product(s), including, without limitation, formulae,
compounds, specifications, designs, chemical and physical data, clinical data,

                                       2
<PAGE>
information concerning synthesis, processes, formulations, applications,
toxicity, operations, regulatory affairs and marketing, that are developed by or
for BioNumerik subsequent to the date of this Agreement and during the term of
this Agreement, subject in all cases to any restrictions that may exist on the
ability of BioNumerik to license such inventions, developments, discoveries or
improvements to ASTA Medica in accordance with the terms of this Agreement.

                  1.7 "BioNumerik Know-How" means all data and information owned
by BioNumerik and useful in the development, manufacture or sale of the
Product(s), including, without limitation, formulae, specifications, designs,
chemical and physical data, clinical data, information concerning synthesis,
processes, formulations, manufacture of the API for the Product(s),
applications, administration to patients, clinical protocols, toxicity,
operations, regulatory affairs and marketing, that have been developed by or for
BioNumerik on or before the date of this Agreement, subject in all cases to any
restrictions that may exist on the ability of BioNumerik to license such
know-how to ASTA Medica in accordance with the terms of this Agreement.

                  1.8 "BioNumerik Patent Rights" means all patents and patent
applications and utility models and utility model applications (also known as
"gebrauchsmuster"), including any addition, continuation, continuation-in-part,
or division thereof or any substitute application therefore; any patent issued
with respect to such patent application; any reissuance, re-examination or
extension, including Supplementary Protection Certificates, of any such patent,
in each case which patent or patent application bears some tangible relationship
to the Product(s) and in which BioNumerik has an ownership or control during the
term of this Agreement. BioNumerik Patent Rights shall include but not be
limited to those patent applications listed on Attachment A hereto. For purposes
of this Agreement, "gebrauchsmuster" shall mean the protection of technical
inventions as defined in the current German Gebrauchsmuster Law or a legal
institutes comparable to the "Gebrauchsmuster" within the Territory in a state
other than Germany where applicable.

                  1.9 "BNP7787" means the compounds described on Attachment B
hereto.

                  1.10 "Budget" means the annual budget approved from time to
time by the Alliance Steering Committee pursuant to Section 4.

                                       3
<PAGE>
                  1.11 "Competitor" of a Party shall mean a company or
organization engaged in the business of discovering, developing, manufacturing
and/or selling any products or services that compete with any of the Product(s)
or any of the other material products that such Party is then developing,
manufacturing, selling or having sold.

                  1.12 "Confidential Information" means all information that is
of a confidential and proprietary nature, including without limitation, trade
secrets, inventions and unpatented Know-How and Improvements and related
technology, and any and all material information either of the Parties hereto
may acquire concerning the financial, business and marketing goals and plans of
the other, including the terms of this Agreement and (a) what has been disclosed
by BioNumerik to ASTA Medica under the existing BioNumerik Confidentiality
Agreement, and (b) what has been disclosed by ASTA Medica to BioNumerik under
the existing Confidentiality Agreement (the "ASTA Medica Confidentiality
Agreement") dated as of September 28, 2000, between ASTA Medica and BioNumerik.

                  1.13 "Costs" means the actual costs of manufacturing,
packaging and shipping, pre-marketing, marketing  and selling Product(s) in the
Territory, which costs are further described on Attachment C hereto.

                  1.14 "Development Plan" means the plan for the development and
commercialization of the Product(s) approved from time to time by the Alliance
Steering Committee pursuant to Section 4.

                  1.15 "Fiscal Year" means ASTA Medica's fiscal year commencing
on January 1 and ending on December 31 of each year.

                  1.16 "Government Regulatory Approvals" means all government
approvals, health registrations and/or permits required for manufacture, sale,
and distribution of Product(s) in the Territory.

                  1.17 "Gross Profits" means Gross Sales less Costs, as
specifically described in Sections 1.18 and 1.13 and on Attachment C hereto.

                  1.18 "Gross Sales" means cumulative post product launch gross
sales in Euros of the Product(s) within the Territory by ASTA Medica or its
Affiliates to third parties or sublicensees, as further described on Attachment
C hereto. Sales between ASTA Medica and its Affiliates are not considered to be
sales to third parties or sublicensees, unless the Affiliate is the end-user of
the Product(s). Gross Sales shall (i) include any direct sales by sublicensees
in the event Product(s) are not sold to the sublicensee by ASTA Medica or its
Affiliates and (ii) also include all value received by ASTA Medica or its
Affiliates in connection with sales by any sublicensees. It is further
understood that BioNumerik's royalty rate and royalties, which are based on
cumulative Gross Sales of Product(s), will not be compromised or reduced as a
result of any sublicenses by ASTA Medica.

                                       4
<PAGE>
                  1.19 "Improvements" means the BioNumerik Improvements and the
ASTA Medica Improvements.

                  1.20 "Know-How" means the BioNumerik Know-How and the ASTA
Medica Know-How.

                  1.21 "Parties" means ASTA Medica and BioNumerik, or if used in
the singular, ASTA Medica or BioNumerik.

                  1.22 "Patents" means those patents that embody the Patent
Rights in the Territory.

                  1.23 "Patent Rights" means the BioNumerik Patent Rights and
the ASTA Medica Patent Rights.

                  1.24 "Product(s)" means any pharmaceutical preparation,
composition, product, method of administration or treatment use, or formulation
for administration that contains BNP7787, a related thiol or disulfide,
metabolites or another related cytoprotective agent period.

BioNumerik has issued patents and patent applications pending on the use,
manufacture and formulations of 2-mercapto ethane sulfonate. These shall be
included in this Agreement and are defined as the chemical compound
2-mercaptoethane sulfonate sodium, all salts and crystalline forms thereof, all
formulations that include 2-mercaptoethane sulfonate sodium or a salt or
crystalline form thereof, and all medical or other uses of 2-mercaptoethane
sulfonate sodium wherein the description of said use identifies mesna, or a salt
or crystalline form thereof, or a formulation that includes 2-mercaptoethane
sulfonate sodium or a salt or crystalline form thereof, as a possible active
agent for effecting the described method of use or formulation in human subjects
or animals.

None of BioNumerik's other agents in discovery or development (including, but
not limited to, karenitecin, MDAM, and preclinical candidates) are included in
this Agreement.

                  1.25 "Product Trademark" means the main (global) trademark for
the Product(s) in the Territory.

                  1.26 "Supply Agreement" has the meaning set forth in Section 7
hereof.

                  1.27 "Territory" shall mean worldwide, except for the United
States of America (and its possessions and territories), Canada (and its
possessions and territories), and Japan (and its possessions and territories).

                                       5
<PAGE>
                  1.28 "Trademarks" means (i) the brand name(s) selected and
owned either by BioNumerik alone or by ASTA Medica to be used for or in
connection with the Product(s) in the Territory (including the Product
Trademark, alternative trademarks to the Product Trademark) and all associated
logos, and (ii) the general reference trade name selected by BioNumerik for
BNP7787 and Product(s).

         2. GRANT OF RIGHTS.

                  2.1 Research and Development License. Subject to the terms of
this Agreement, BioNumerik hereby grants to ASTA Medica and its Affiliates an
exclusive license in the Territory under the BioNumerik Patent Rights,
BioNumerik Know-How and BioNumerik Improvements to conduct and have conducted
research and development (including studies and clinical trials) of the
Product(s) in the Territory for the purpose of obtaining Government Regulatory
Approvals in the Territory.

                  2.2 License to Market, Sell and Distribute. Subject to the
terms of this Agreement, BioNumerik hereby grants to ASTA Medica and its
Affiliates an exclusive license in the Territory under the BioNumerik Patent
Rights, BioNumerik Know-How and BioNumerik Improvements to make, have made, use,
market, distribute, sell, and offer for sale the Product(s) in the Territory.

                  2.3 Sublicenses. ASTA Medica shall have the right to
sublicense the rights granted under Sections 2.1 and 2.2 to third parties in the
Territory subject to the prior written consent of BioNumerik, which will not be
unreasonably withheld. ASTA Medica and BioNumerik agree that BioNumerik shall
have reasonable grounds to object if (i) the aggregate of all such sublicensees
would reasonably be expected to exceed [**] of the total European market for
the Product; or any single sublicensee would reasonably be expected to exceed
[**] of the total Territorial market for the Product, or (ii) the overall
compensation structure of the sublicense terms are not fair to BioNumerik. ASTA
Medica shall remain fully responsible to BioNumerik for the actions or failure
to act of any of its sublicensees.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       6
<PAGE>
                  2.4 Canada Right of First Offer. In the event BioNumerik or
its Affiliates do not wish to pursue marketing, distribution and/or sale of the
Product(s) in Canada on their own, BioNumerik shall provide ASTA Medica with
written notice (the "Canada Notice") to such effect. ASTA Medica shall have a
right of first offer to negotiate with BioNumerik to obtain a license with
respect to the Product(s) in the territory of Canada. The first offer right
granted herein will expire 45 days after ASTA Medica's receipt of the Canada
Notice. If no proposal to obtain a license with respect to the Product(s) for
the territory of Canada is made to BioNumerik by ASTA Medica within such 45 day
period, ASTA Medica's right of first offer shall terminate. In the event ASTA
Medica does make a proposal for the territory of Canada within such time period,
then BioNumerik and ASTA Medica will negotiate in good faith during the
remainder of such 45 day notice period and for an additional 90 day period (the
"Negotiation Period") in an effort to enter into a license agreement for such
territory on mutually agreeable terms. If a license has not been executed by the
end of the Negotiation Period, then BioNumerik shall be free to enter into a
third party license and/or alliance with respect to the Product(s) for the
territory of Canada, provided the economic terms of such license and/or alliance
are no more favorable to such third party than the terms last proposed by ASTA
Medica before expiration of the Negotiation Period.

                  2.5 Retention of Rights. BioNumerik shall retain the right for
itself and its Affiliates to use the BioNumerik Patent Rights, BioNumerik
Know-How, and BioNumerik Improvements in the Territory without cost for internal
research and development purposes, for purposes of co-developing the Product(s)
in the Territory with ASTA Medica as approved by the Alliance Steering
Committee, for purposes of manufacturing the Product(s) in the Territory in
accordance with this Agreement, and for purposes that do not relate to the
Product(s). In addition, BioNumerik, its Affiliates, and other parties
previously or hereafter authorized by BioNumerik shall retain the right to
conduct and have conducted research and development (including studies and
clinical trials) of the Product(s) throughout the world for the purpose of (a)
obtaining regulatory approvals outside the Territory, and (b) obtaining
additional data and information regarding the Product(s). BioNumerik will not
conduct any such research and development in the Territory without the prior
consent of ASTAMedica, which consent will not be unreasonably withheld.
BioNumerik may continue to conduct its existing preclinical studies and Phase I
clinical trials relating to the Product(s) in the Territory. In addition,
nothing contained herein is intended to limit the right of ASTA Medica or
BioNumerik to discover, develop, market, or sell other therapeutic products or
technologies throughout the world.

                  2.6 Provision of Know-How. As soon as practicable after the
date of this Agreement and on a regular basis thereafter during the term of this
Agreement, BioNumerik will, subject to the

                                       7
<PAGE>
confidentiality and other terms contained herein, make additional BioNumerik
Know-How available to ASTA Medica.

                  2.7 Distribution. Except as expressly provided in this
Agreement or by a separate written mutual agreement between the Parties,
BioNumerik shall not directly or indirectly distribute or sell Product(s) in the
Territory. Except as expressly provided in this Agreement or by a separate
mutual written agreement between the Parties, ASTA Medica shall not directly or
indirectly manufacture Product(s) to be sold in the Territory or manufacture,
market, distribute or sell Product(s) outside the Territory, unless otherwise
permitted pursuant to a separate agreement that may be entered into by the
Parties pursuant to Section 7.2.

         3. MANAGEMENT OF RELATIONSHIP.

                  3.1 Steering Committee.

                     (a) Formation. Promptly upon execution of this Agreement,
BioNumerik and ASTA Medica will establish an Alliance Steering Committee. The
Alliance Steering Committee shall manage all aspects of the business and
strategic relationship between the Parties with respect to the development of
the Product(s) in the Territory in accordance with the terms of this Agreement.

                     (b) Responsibilities. The Alliance Steering Committee will
have responsibility for overseeing the implementation, performance and
coordination of all development, regulatory, manufacturing, distribution,
selling and marketing activities relating to the Product(s) in the Territory and
for effective communication regarding operations and strategies that are
important for the development of the Product(s). As part of its
responsibilities, the Alliance Steering Committee shall be responsible for
approving the Product Development Plan and Budget. The Alliance Steering
Committee will also monitor the performance of research and development work
relating to the Product(s) in the Territory. The Parties shall report to the
Alliance Steering Committee on all significant clinical and regulatory issues
relating to the Product(s), and the Alliance Steering Committee shall make
recommendations and provide strategic guidance with respect to such issues.

                     (c) Composition. The Alliance Steering Committee shall be
comprised of at least 2 and up to 4 members total as may be agreed to from time
to time by ASTA Medica and BioNumerik. The initial Alliance Steering Committee
will be comprised of Dr. Frederick Hausheer and Dr. Jose-Maria Gimenez-Arnau
who will serve as Co-Chairs of the

                                       8
<PAGE>
Alliance Steering Committee. The selection of Alliance Steering Committee
members shall be made by ASTA-Medica and BioNumerik Pharmaceuticals, Inc. as
needed from time to time. The Alliance Steering Committee members shall be
qualified representatives of each company with expertise in oncology drug
development and commercialization operations. The Alliance Steering Committee
will be comprised of an equal number of members from ASTA Medica and BioNumerik,
provided however, that each Party must have on the Alliance Steering Committee
employees holding the following positions: Head of Research and Development and
Head of Sales and Marketing. On behalf of BioNumerik, Dr. Hausheer will
communicate strategies, developments and operations relating to the Product(s)
to the Alliance Steering Committee.

                     (d) Meetings. The Alliance Steering Committee will meet at
least quarterly (in Europe, U.S., or by telephone, video conference or internet
- by mutual consent) each calendar year prior to commercialization of the
Product(s) in the Territory. In addition, either Party may request additional
meetings as reasonably required. The Co-Chairs of the Alliance Steering
Committee will be responsible for providing an agenda for each meeting of the
committee at least 10 days in advance of such meeting and shall prepare written
minutes of all committee meetings in reasonable detail. The Co-Chairs shall
distribute a draft or final written version of such minutes to all members of
the Alliance Steering Committee within 20 days after the relevant meeting.

                  3.2 Project Team. The Alliance Steering Committee will
establish a Project Team that will be responsible for managing the day-to-day
development and registration aspects of the Development Plan. The Project Team
will be comprised of the various employees of each Party that are required for
the successful development and registration of the Product(s) in the Territory.
The Project Team will meet regularly, based on a written schedule and other
mutually agreeable considerations as needed to insure effective communication,
coordination and all related operations for development and marketing of the
Product(s) in the Territory.

                  3.3 Additional Teams and Assistance. The Alliance Steering
Committee may establish such other teams or working groups, as it deems
necessary or desirable in connection with the development and commercialization
of the Product(s).

                                       9
<PAGE>
                  3.4 Cooperation. Each Party will utilize its reasonable best
efforts to act reasonably and in good faith to avoid deadlocks at either the
Alliance Steering Committee or Project Team level and to ensure the successful
operations of both the Alliance Steering Committee and the Project Team. To this
end, each Party will make available to both the Alliance Steering Committee and
the Project Team that Party's knowledge and expertise with regard to the
Product(s) and to the development and registration of products of this nature.

                  3.5 Voting and Dispute Resolution. Each of ASTA Medica and
BioNumerik shall have one vote on the Alliance Steering Committee and on the
Project Team. A unanimous vote by both Parties shall be required for a decision
by the Alliance Steering Committee or the Project Team. A quorum of the Alliance
Steering Committee or the Project Team shall exist only if at least one
representative from each Party with authority to cast the vote of the Party on
the matter before the Alliance Steering Committee or the Project Team, as the
case may be, is present. If the Project Team is unable to reach a decision on
any matter, the Project Team shall refer such matter to the Alliance Steering
Committee. If the Alliance Steering Committee is unable to reach a mutual
agreement on any matter, including any matter referred to the Alliance Steering
Committee by the Project Team, the Alliance Steering Committee shall promptly
conduct good faith discussions in an effort to resolve such matter in a
reasonable and mutually satisfactory manner. If the matter is not resolved by
the Alliance Steering Committee representatives of BioNumerik and ASTA Medica
within 60 days after the commencement of such discussions, either Party may
request, in writing, that the matter be resolved by binding arbitration in
accordance with the provisions of Article 20.9 of the Agreement.

                  3.6 Costs of Maintenance and Operation. Each of ASTA Medica
and BioNumerik will bear its own costs and expenses relating to the maintenance
and operation of the Alliance Steering Committee and the Project Team. The
members of the Alliance Steering Committee and the Project Team will each serve
without any additional compensation.

                                       10
<PAGE>

      4.    DEVELOPMENT PLAN AND COSTS.

            4.1   Development Costs. ASTA Medica shall pay all research and
development expenses in order to develop and commercialize the Product(s) in the
Territory. Such costs will include, without limitation, all costs in order to
carry out the Development Plan, including all costs of any non-clinical or
clinical tests or studies required by any applicable regulatory agency in the
Territory, including any associated manufacturing costs. BioNumerik will be
responsible  for paying [**] of the premarketing costs for the Product(s) in
the Territory prior to launch, which contribution amount by BioNumerik will not
exceed 1,533,875 Euros in the aggregate. ASTA Medica will provide BioNumerik
with a summary of such premarketing costs on a quarterly basis, and BioNumerik
will make payment to ASTA Medica for BioNumerik's portion of such premarketing
costs [**] after receipt of the summary from ASTA Medica. BioNumerik is free to
have the calculation of such costs audited in the same manner as provided in the
last sentence of Section 5.6. If BioNumerik determines to conduct a clinical
study for the Product(s) in the Territory on its own, after obtaining ASTA
Medica's consent, BioNumerik shall pay the costs of such study, unless otherwise
agreed by the Parties. If ASTA Medica determines to conduct a clinical study for
the Product(s) outside of the Territory on its own, after obtaining BioNumerik's
consent, ASTA Medica shall pay the costs of such study, unless otherwise agreed
by the Parties.

            4.2   Government Approvals and Clinical Trials.

                  4.2.1.   ASTA Medica agrees at its sole expense to (a) conduct
or cause to be conducted all clinical trials and other studies of any nature of
the Product(s) necessary or desirable for obtaining Government Regulatory
Approvals and (b) prepare and submit all documents necessary or desirable for
obtaining Government Regulatory Approvals. The Alliance Steering Committee will
mutually determine the priority of each country in the Territory for
development, registration and marketing of the Product(s) within a reasonable
period of time following the date of this Agreement. The Alliance Steering
Committee will update the priority list on a semi-annual basis. In connection
therewith, ASTA Medica shall, at its own expense and in accordance with the
priorities determined by the Alliance Steering Committee, apply for all health
registrations and Government Regulatory Approvals required to execute and to
perform this Agreement. To the extent permitted by laws in the Territory and if
requested by ASTA Medica, BioNumerik agrees to assist and support the process of
obtaining the Government Regulatory Approvals by providing input and assistance
from Dr. Frederick H. Hausheer regarding the design and conduct of non-clinical
studies, clinical trials, preparation of regulatory submissions and review,
analysis and presentation of laboratory data. During the term of this Agreement,
ASTA Medica shall be the marketing, development and

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       11
<PAGE>
distribution authorization holder of the Product(s) in the Territory unless
otherwise agreed to by the Alliance Steering Committee. ASTA Medica shall keep
BioNumerik regularly and fully informed of the status of the Government
Regulatory Approvals process on a current basis and furnish BioNumerik upon
BioNumerik's reasonable request with copies of all of the documents, data and
other information supplied to or received from applicable government authorities
in connection with the applications for the Government Regulatory Approvals.
Upon receipt of the Government Regulatory Approvals, ASTA Medica shall promptly
furnish BioNumerik copies or other satisfactory evidence thereof. In addition,
ASTA Medica may conduct research and development (including studies and clinical
trials) of the Product(s) outside the Territory for the purpose of supporting
the development and commercialization of the Product(s) in the Territory.
BioNumerik will have the right to review and consent to any such studies and
clinical trials outside the Territory in advance of their commencement, which
consent will not be unreasonably withheld.

                  4.2.2    ASTA Medica shall have ownership (including
reservation of the right to use in the Territory in accordance with this
Agreement) of all data and results obtained by ASTA Medica from the non-clinical
studies, clinical trials and related testing conducted pursuant to Section 4.1
and 4.2.1 (the "ASTA Medica Data and Results"). Each of ASTA Medica and
BioNumerik shall have the right to use the ASTA Medica Data and Results as
described in this Agreement, unless otherwise agreed by the Parties hereto. ASTA
Medica shall also have the right to use data and results obtained by BioNumerik
from the non-clinical studies, clinical trials and related testing conducted for
the Product(s) outside the Territory, provided that such use by ASTA Medica
shall be for the purpose of supporting the development and commercialization of
the Product(s) in the Territory and shall be subject to any existing limitations
on the ability of BioNumerik to provide such data and results to ASTA Medica.

            4.3   Development Plan and Budget. The initial Development Plan and
initial Budget agreed to by the Parties will be developed by the Parties with
final review and approval by the Alliance Steering Committee. The Development
Plan and Budget will be updated by the Alliance Steering Committee on at least a
quarterly basis. Prior to the start of each calendar year, the Alliance Steering
Committee shall meet to review and approve a Development Plan and Budget for the
following calendar year. No material deviations (e.g., major changes in clinical
study design, patient populations, clinical trial endpoints, or the analysis of
such endpoints) from the Development Plan or Budget will occur without prior
approval by the Alliance Steering Committee. The Development Plan will include
the following elements: (a) a clinical trial program for the Product(s) in the
Territory, (b) a Product Registration Plan, (c) a Publication Plan, and (d) a
Distribution, Selling and Marketing Plan for the Product(s). No company
sponsored clinical trial shall be commenced for the Product(s) in the Territory
without the approval of the Alliance Steering Committee. The Budget detail will
contain specific estimates of allocation of administrative and finance costs,
country or

                                       12
<PAGE>
region-specific allocation of "sales force time and effort" (as defined in
Section 5.6), and country specific-profit and loss estimates.

            4.4   Promotional Materials involving BioNumerik and Labeling. To
the extent permissible by law, the Product(s) distributed in the Territory shall
be represented in all labeling and other documentation as jointly developed by
ASTA Medica and BioNumerik. ASTA Medica shall assure inclusion, consistent with
the laws of each country in the Territory, of BioNumerik's name, logo and other
identification in any promotional materials, which inclusion shall be overseen
at the Alliance Steering Committee level. ASTA Medica agrees that promotional
materials for the Product(s) in the Territory shall contain the statement: "
Under license from BioNumerik Pharmaceuticals, Inc." and shall also display the
BioNumerik trademark wherever permitted by law. Product(s) marketed and sold by
ASTA Medica hereunder shall also be marked with appropriate patent numbers or
indicia at BioNumerik's request, subject to ASTA Medica's consent, not to be
unreasonably withheld.

      5.    LICENSE FEES AND ROYALTIES.

            5.1   License Fees.

                  As partial consideration of the rights hereby granted, ASTA
Medica shall pay to BioNumerik a fixed fee of U.S. $15,000,000(Fifteen Million
U.S. Dollars) immediately upon the execution of this Agreement, which fee shall
be non-refundable except as provided in Section 14.5.

            5.2   Royalties. ASTA Medica shall pay BioNumerik a sliding scale
percentage of Gross Profits per Fiscal Year based on the cumulative Gross Sales
within the Territory during the term of this Agreement. All payments to
BioNumerik by ASTA Medica shall be in U.S. dollars.

            Accordingly, ASTA Medica shall pay BioNumerik the following amounts:

                  (a) [**] of the Gross Profits for up to [**] of cumulative
Gross Sales of Product(s) in the Territory;

                  (b) [**] of the Gross Profits from [**] of cumulative Gross
Sales of Product(s) in the Territory; and

                  (c) [**] of the Gross Profits for [**] or more of cumulative
Gross Sales of Product(s) in the Territory.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       13
<PAGE>

            5.3   Expiration of Royalty Obligations. The royalty obligations set
forth in Section 5.2 above shall expire on a country-by-country basis in those
countries in which a BioNumerik Patent Right covers the use or sale of
Product(s), effective as of the date upon which the use or sale of Product(s) in
such country would no longer infringe a valid claim of a BioNumerik Patent Right
in the absence of the rights granted hereunder, provided however that (a) all
royalty obligations shall continue on a country-by-country basis until the last
patent expiry of the medical use and/or formulation patent applications and/or
patents which claim the use and/or marketing approved formulation of BNP7787 as
listed in Attachment A, such as cisplatin, carboplatin and/or taxane
derivatives, and (b) all royalty obligations shall continue during the time that
any patent application included in the Patent Rights is being prosecuted. If a
new patent is issued in a particular country with respect to the Product(s)
where the royalty obligations have or would have otherwise expired in such
country, the royalty obligations contained in Section 5.2 shall be renegotiated
in accordance with their terms with respect to such country, provided that (a)
the Parties shall assess the new patent together using an estimated net present
value estimate of the potential economic outcome of such new patent that is
agreed to provide a [**] net present value to BioNumerik and ASTA Medica, and
(b) the lower limit of the royalty to BioNumerik with respect to such new patent
in such country will be [**] of the Gross Profits with respect to such country,
if the patent issued protects marketing exclusivity of the Product in such
country. Royalties on Product(s) shall also continue to be paid by ASTA Medica
pending final resolution of any litigation or dispute involving ASTA Medica,
BioNumerik, the Product(s) or the Patent.

            5.4   Inclusion of Sublicense Fees. All payments or fees of any kind
received by ASTA Medica or its Affiliates from any sublicensee of the Product(s)
shall be included in Gross Sales and Gross Profits (including, without
limitation, situations where such payments and fees are made prior to product
launch), and BioNumerik shall be paid a royalty on all such payments and fees in
accordance with Section 5.2

            5.5   Sales Forecast and Payment. Within 45 days of the beginning of
each Fiscal Year, the Alliance Steering Committee will agree on the forecast of
sales for such Fiscal Year. The forecast will include a country specific
estimate of sales in the Territory. Based on this forecast, BioNumerik will
receive quarterly installments of the royalty amount expected to be due to
BioNumerik according to the scale described in Section 5.2 at the end of each
calendar quarter from ASTA Medica.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       14
<PAGE>

            5.6   Forecast Adjustment. Within 45 days after the end of each
Fiscal Year the payments according to the forecasts will be compared with the
actual Gross Sales and Gross Profits. If the aggregate estimated payments made
by ASTA Medica to BioNumerik for such year exceed the actual royalty owing for
such year, BioNumerik shall refund the difference within 45 days of such
determination. If the aggregate estimated payments made by ASTA Medica to
BioNumerik for such year are less than the actual royalty owing for such year,
ASTA Medica shall pay BioNumerik the difference within 45 days of such
determination. ASTA Medica's accountant, KPMG, will review all data and
calculations of royalty amounts and payments. This will be done no later than
the end of February of the following Fiscal Year. In addition, the records
maintained by ASTA Medica for calculating Costs in determining the royalty shall
include specific line items for allocation of administrative and finance
costs (as defined in Attachment C), country or region-specific allocation of
Product marketing, promotion, distribution, and sales capacity (specified in
terms of budget and personnel) defined as "sales force time and effort", and
country specific- Product sales priority and profit and loss amounts. BioNumerik
is free to have such data and calculations fully audited at its own cost by
another accounting firm selected by BioNumerik and ASTA Medica will disclose all
such data and calculations to BioNumerik's auditors on a confidential basis.

      6.    INFORMATION SHARING.

            6.1   Sharing of Information. ASTA Medica will keep BioNumerik
regularly and fully informed of the non-clinical and clinical development
progress, including discussions and correspondence with regulatory authorities
in the Territory for the Product(s), and ASTA Medica shall provide BioNumerik
with copies of all data and developments that arise from research and
development carried out by or on behalf of ASTA Medica on the Product(s)
pursuant to this Agreement, including all Government Regulatory Approvals for
Product(s) in the Territory. Without any further obligation to ASTA Medica,
BioNumerik (and its designated Affiliates, assignees and sublicensees) are
hereby granted the right to use the ASTA Medica Data and Results, for the
purpose of supporting non-clinical studies, clinical trials and product
regulatory approval and development in areas outside of the Territory, but
excluding Japan.

                                       15
<PAGE>
            6.2   BioNumerik Information. BioNumerik shall provide ASTA Medica
with copies of all information generated or controlled by it in the course of
satisfying regulatory requirements in the United States, Japan and/or other
areas outside the Territory with respect to the Product(s) that may be useful or
necessary in obtaining Government Regulatory Approvals in the Territory, such as
IND applications, annual reports, protocol amendments, IND amendments,
promotion, marketing, sales, manufacturing and related documents and information
(collectively, the "BioNumerik Data and Results"). Without any further
obligation to BioNumerik, ASTA Medica (and its designated Affiliates, assignees
and sublicensees) are hereby granted the right to use the BioNumerik Data and
Results, for the purpose of supporting non-clinical studies, clinical trials and
regulatory approval and development of Product(s) in the Territory. For purposes
hereof, the term "Data and Results" shall mean the ASTA Medica Data and Results
and the BioNumerik Data and Results.

            6.3   Additional Information Sharing. In recognition of the
significant importance and benefit of sharing with ASTA Medica all data and
information generated with respect to the Product(s) outside the Territory,
BioNumerik agrees to use its reasonable best efforts to provide ASTA Medica with
the opportunity to enter into a Confidentiality Agreement with Grelan
Pharmaceutical Co., Ltd., BioNumerik's partner for the development of the
Product in Japan ("KI Pharma"), for the purpose of direct communication and
exchange of know-how and other confidential information regarding the
Product(s). BioNumerik shall encourage KI Pharma to enter into such an agreement
with ASTA Medica. ASTA Medica agrees that if KI Pharma agrees to share with ASTA
Medica all data and information generated by KI Pharma with respect to the
Product(s) for the purpose of supporting the development of the Product(s) in
the Territory, then ASTA Medica will, on similar terms, agree to share with KI
Pharma all data and information generated by ASTA Medica with respect to the
Product(s) for the purpose of supporting the development of the Product(s) in
Japan and its possessions and territories. ASTA Medica will promptly provide
BioNumerik with a copy of all communications, data and information shared
between KI Pharma and ASTA Medica that are important to the development,
marketing and manufacturing of the Product(s). BioNumerik will endeavor to
organize and facilitate interactions and communications between ASTA Medica and
KI Pharma regarding the Product(s). Dr. Hausheer will oversee these efforts and
the Parties will endeavor to have a meeting with all such companies at least
once each year. In addition, BioNumerik agrees to use its reasonable best
efforts to provide that any

                                       16
<PAGE>
agreement hereafter signed with respect to a license for commercial distribution
of the Product(s) in areas outside the Territory will provide that the licensee
under such license will share with ASTA Medica all data and information
generated by such licensee with respect to the Product(s) for the purpose of
supporting the development of Product(s) in the Territory. In the event a
prospective licensee for the commercial distribution of the Product(s) in areas
outside the Territory will not agree to the sharing of all data and information
as provided above, BioNumerik will consult with ASTA Medica prior to signing any
license agreement with such party and BioNumerik will use its reasonable best
efforts to facilitate and provide an opportunity for discussion between ASTA
Medica, BioNumerik and such prospective licensee with respect to a mutually
satisfactory arrangement for the sharing of data and information. For purposes
of this Agreement, "reasonable best efforts" shall mean those reasonable
commercial efforts that would be used by reasonable business persons in a
similar situation.

      7.    MANUFACTURING.

            7.1   Manufacturing Rights. BioNumerik will retain all manufacturing
rights related to the Product(s) in all parts of the world (including the
Territory), subject to ASTA Medica's non-exclusive option described in Section
7.2.

            7.2   Non-Exclusive Manufacturing Option for Territory. ASTA Medica
is hereby granted the option to bid to manufacture Product(s) for development
and regulatory approval and/or sale in the Territory. From time to time during
the term of this Agreement, ASTA Medica shall, at its option, provide BioNumerik
with a bid containing the price, delivery amount and other material terms under
which it would manufacture Product(s) for the Territory on a non-exclusive
basis. It is the hope of the Parties that ASTA Medica will be a significant
manufacturer of Product supply in the Territory, subject to meeting the
competitive requirements of price, quality, supply, delivery and other material
terms relative to other potential or active manufacturers. If such bid is on
substantially competitive terms with BioNumerik's other alternatives for
manufacturing Product(s) for the Territory, then BioNumerik and ASTA Medica
will negotiate in good faith to enter into a supply agreement providing for the
manufacture by ASTA Medica of a portion of the Product(s) to be supplied for
the Territory, which portion will be determined by BioNumerik. In the event of
any unsuccessful bid by ASTA Medica, BioNumerik will describe to ASTA Medica
the categories in which its bid was deemed not competitive. In the absence of
any bid from ASTA Medica to manufacture Product(s) on substantially competitive
terms to BioNumerik's other manufacturing alternatives, BioNumerik shall be free
to utilize such other alternatives for the manufacture of Product(s) in the
Territory.

                                       17
<PAGE>

            7.3   Pre-Commercial Manufacturing. BioNumerik will furnish ASTA
Medica with all supplies of Product(s) required by ASTA Medica in order to
conduct the pre-commercialization studies and clinical trials described in
Sections 4.1 and 4.2, which supplies shall be furnished by BioNumerik to ASTA
Medica at a price equal to BioNumerik's actual cost to manufacture the
materials (including a reasonable overhead amount in compliance with U.S.
GAAP), plus freight, transport, insurance, and customs and duty charges
incurred in delivering the materials to ASTA Medica, but shall exclude any
profit element.

            7.4   Commercial Supply Agreement. Following execution of this
Agreement, BioNumerik agrees to finalize its processes for the manufacture of
Product(s) as shall be agreed from time to time between itself and ASTA Medica.
Within 24 months prior to the estimated time of the first commercial sale of
Product(s) in the Territory, ASTA Medica and BioNumerik shall enter into a
commercial supply agreement (the "Supply Agreement") to be negotiated in good
faith and to reflect such terms and conditions as shall be reasonably necessary
to govern the manufacture and supply of Product(s) for sale and distribution in
the Territory.

      The Supply Agreement will provide among other things that:

                  (a)   Not later than the end of each calendar year that
commences after execution of the Supply Agreement, ASTA Medica will supply to
BioNumerik an estimate of its requirements of the amount of API or finished
Product(s) in the Territory during the following [**] years, and will update
this estimate at six-month intervals. BioNumerik will notify ASTA Medica within
90 days of receipt of such estimate if it (or its Affiliates) will be unable to
supply the whole or any part of the requirements described in such estimate.
Together with the [**] estimate, ASTA Medica will deliver to BioNumerik firm
orders for its estimated requirements of Product(s) not less than 12 months in
advance of the required date of delivery. Within thirty (30) days of its receipt
of such firm order, BioNumerik shall confirm such order in writing and fulfill
such orders in accordance with ASTA Medica's required date of delivery provided
the quantities specified therein do not exceed those quantities contained in the
previous estimate for the same period and provided that BioNumerik has not
previously advised ASTA Medica that it will be unable to supply all or part of
such quantities.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       18
<PAGE>
                  (b)   If BioNumerik (or its Affiliates) are unable to meet the
requirements of ASTA Medica and its Affiliates and sublicensees for commercial
quantities of Product(s), then ASTA Medica may fill all of its remaining supply
requirements in excess of the amount provided by BioNumerik (and its Affiliates)
from a third party or parties. In such event, (i) BioNumerik shall grant a
license to ASTA Medica under the BioNumerik Patent Rights, BioNumerik Know-How,
and BioNumerik Improvements to manufacture and have such third party manufacture
Product(s) for the purpose of allowing such remaining supply requirements to be
filled, and (ii) BioNumerik shall also provide such information and reasonable
assistance as may be necessary to allow such third party to manufacture
Product(s) for the purpose of allowing such remaining supply requirements to be
filled.

                  (c)   The cost of the Product(s) under the Supply Agreement
will be based on [**].

                  (d)   ASTA Medica shall be entitled to have BioNumerik's cost
of manufacture and overhead confirmed by an independent firm of accountants to
which BioNumerik has no reasonable objection, but not more than once in any 12
month period, provided, however, that such firm of accountants shall only report
to ASTA Medica the amount of such costs, including overhead, and shall keep
confidential all other information acquired in the course of the examination.
ASTA Medica shall pay the cost of any such audit and the audit shall be
conducted so that it will not disrupt BioNumerik's ongoing business activities.

      The Parties in good faith shall negotiate all other terms of supply and
purchase to be included in the Supply Agreement.

            7.5   No Infringing Manufacture or Supply. In any event, BioNumerik
shall not be required to manufacture or supply Product(s) pursuant to this
Agreement if by so doing it would be liable to suit for infringement or
contributory infringement of the intellectual property rights of a third party.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       19
<PAGE>
      8.    DILIGENCE.

            8.1   General Diligence Efforts. ASTA Medica agrees to use its best
efforts to commercialize or cause to be commercialized the Product(s) in the
Territory as soon as reasonably plausible, taking into account external
conditions (e.g., economic, demographic, war or change in market) which would
reasonably be expected to adversely affect commercialization of the Product. As
part of such agreement, ASTA Medica shall use best efforts to commercialize,
promote, distribute, sell and establish the Product(s) in accordance with the
specified list of countries in the Territory in accordance with the development
priorities determined by the Alliance Steering Committee as described in section
4.2.1.

            8.2   Target Development and Commercialization Plan. In addition to
the above general diligence requirements, ASTA Medica shall meet the Development
Plan targets determined by the Alliance Steering Committee for the Product(s).
If any of the specified targets are not met with respect to the Product(s), and
such targets continue to remain unmet for a period of 60 days or greater
following notice to ASTA Medica by BioNumerik, then the Parties hereto shall
discuss and decide in good faith how to solve the problem. If (a) the specified
development and commercialization targets contained in the Development Plan and
determined by the Alliance Steering Committee for the Product(s) are not met on
an annual basis for three consecutive years, (b) the Product(s) does not
receive Government Regulatory Approval to sell and distribute such product in at
least one country in Europe within 4 years after the date of this Agreement, or
(c) ASTA Medica completely ceases development, marketing, or regulatory activity
with respect to the Product(s) in one or more countries in the Territory and
such cessation continues for more than 60 days, then all licenses granted by
BioNumerik hereunder, and to the BioNumerik Improvements, BioNumerik Patent
Rights, and BioNumerik Know-How shall terminate (either for the entire Territory
with respect to clause(a) or clause(b) of this sentence or on a country by
country basis with respect to clause(c) of this sentence), all right, title, and
interest in the Product(s) shall automatically revert to BioNumerik (either for
the entire Territory with respect to clause(a) or clause(b) of this sentence or
on a country by country basis with respect to clause(c) of this sentence), and
all transferable elements of government approvals, registrations or other
regulatory approvals and applications shall be promptly transferred to
BioNumerik, provided that such rights shall not revert to BioNumerik if the
failure to meet such target, take such action, or receive such approval, as the
case may be, was caused in substantial part by the actions or failure to act of
BioNumerik. An extension of the time to meet the development performance
requirements in the previous sentence may be granted upon mutual agreement
between ASTA Medica and BioNumerik.

      9.    PATENT MATTERS.

            9.1   BioNumerik Patent Maintenance. BioNumerik will be responsible
for prosecuting, maintaining and defending the patents covered by the BioNumerik
Patent Rights and BioNumerik will own all BioNumerik Patent Rights. The costs
for prosecuting and maintaining such patents shall be at BioNumerik's own
expense and the costs of defending such patents in the Territory will be borne
[**] by BioNumerik and [**] by ASTA Medica. BioNumerik will, during the term of
this Agreement, use reasonable best efforts to continue to obtain and maintain
additional patent protection for the Product(s). BioNumerik will regularly
advise ASTA Medica as to the progress of its patent applications and
registrations in the Territory relating to the Product(s). BioNumerik will
provide ASTA Medica with copies of all official actions from the patent offices
in the Territory. Any reply to those office actions dealing with the scope of
the claims will only be submitted by BioNumerik or its representative(s) after
ASTA Medica's prior input, which input will be promptly given and will not be
unreasonably withheld. ASTA Medica and BioNumerik

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       20
<PAGE>
will develop a joint strategy as to patent strategy and prosecution in the
Territory with respect to the Product(s). In addition, BioNumerik will advise
ASTA Medica as to the patent strategy and prosecution outside the Territory with
respect to the Product(s). BioNumerik agrees not to file patents on or make use
of any Confidential Information that ASTA Medica has provided or disclosed to
BioNumerik unless it has obtained the prior written consent of ASTA Medica to
such filings or use. BioNumerik agrees to submit confidential pharmacological
and clinical data to patent offices in the Territory when necessary for
prosecution of patents by BioNumerik.

            9.2   ASTA Medica Patent Maintenance and Assistance. ASTA Medica
will be responsible for prosecuting, maintaining, and defending the patents
covered by the ASTA Medica Patent Rights and ASTA Medica will own all ASTA
Medica Patent Rights. The costs for prosecuting and maintaining such patents
shall be at ASTA Medica's own expense and the costs of defending such patents in
the Territory will be borne [**] by ASTA Medica and [**] by BioNumerik. ASTA
Medica will regularly advise BioNumerik as to the progress of its patent
applications and registrations in the Territory relating to the Product(s). ASTA
Medica will provide BioNumerik with copies of all official actions from the
patent offices in the Territory. Any reply to those office actions dealing with
the scope of the claims will only be submitted by ASTA Medica or its
representative(s) after BioNumerik's prior input, which input will be promptly
given and will not be unreasonably withheld. ASTA Medica agrees not to file
patents on or make use of any Confidential Information that BioNumerik has
provided or disclosed to ASTA Medica unless it has obtained the prior written
consent of BioNumerik to such filings or use. In addition, ASTA Medica will
advise BioNumerik as to patent strategy and prosecution in the Territory with
respect to the Product(s).

            9.3   BioNumerik Patent Representations. BioNumerik represents and
warrants to ASTA Medica that BioNumerik owns or has applied for all patents,
patent rights, inventions and know-how described in the BioNumerik Patent Rights
and necessary to grant the licenses granted herein. BioNumerik further
represents and warrants that, to the best of its knowledge, the manufacture,
use, sale or development of the Product(s) pursuant to this Agreement will not
infringe or conflict with any third party right or patent and that BioNumerik is
not aware of any pending third party patent application that, if issued, would
be infringed by the manufacture, use, sale or development of the Product(s)
pursuant to this Agreement. BioNumerik has no knowledge that any infringement
referred to above has occurred or of any other litigation or threat of
litigation involving the Product(s), and BioNumerik has not been notified and is
not aware of any actual or potential claims of such infringement or other
litigation involving the Product(s).

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       21
<PAGE>
            9.4   ASTA Medica Patent Representations. ASTA Medica represents and
warrants to BioNumerik that ASTA Medica has no knowledge that any infringement
or conflict with any third party involving the Product(s) has occurred or of any
other litigation or threat of litigation involving the Product(s). ASTA Medica
has not been notified and is not aware of any actual or potential claims of such
infringement or other litigation involving the Product(s). ASTA Medica has had
the opportunity to analyze and perform due diligence on the current BioNumerik
patent portfolio and the patent filing and prosecution status regarding the
Product(s).

            9.5   Enforcement of Patents and Proprietary Rights.

                  (a)   To the extent allowable by law, BioNumerik shall have
the sole first opportunity to institute and prosecute proceedings or suits
("Suits") for infringement of the BioNumerik Patent Rights and/or patents and
proprietary rights regarding the Product(s) in the Territory. BioNumerik shall
promptly advise ASTA Medica of any such Suit, and BioNumerik and ASTA Medica
shall develop a joint strategy with respect to all such Suits and other third
party intellectual property litigation regarding the Product(s) in the Territory
("Other IP Litigation"). ASTA Medica may join as a party to any Suit brought by
BioNumerik, and to the extent required to properly bring such litigation, ASTA
Medica shall join as a party to any Suit brought by BioNumerik in the Territory.
In the event BioNumerik refrains from initiating any Suit, ASTA Medica may bring
such Suit on its own, and if BioNumerik is required as a party to properly bring
or join such Suit, BioNumerik shall, upon ASTA Medica's request, bring such Suit
or join as a party to such Suit. BioNumerik shall have the sole right to decide
to accept or reject any settlement offer regarding the Suits or Other IP
Litigation, provided that the acceptance of any such settlement that negatively
affects ASTA Medica's rights hereunder or the ASTA Medica Patent Rights must be
consented to by ASTA Medica, which consent will not be unreasonably withheld. In
addition, a response regarding a consent requested by BioNumerik will be
provided by ASTA Medica within 5 business days after BioNumerik's request. , If
ASTA Medica is bringing any Suit without BioNumerik, then any settlement
agreement would have to be approved by both Parties to the extent that it may
affect the BioNumerik Patent Rights. The Parties will meet in good faith with
any third party licensee of the Product(s) to discuss the possible contribution
by such third party to the costs of any Suit.

                  (b)   Except as otherwise expressly provided herein, all legal
expenses and costs in such Suits or Other IP Litigation (including attorneys'
fees) (the "Legal Expenses") when jointly prosecuted will be borne 50% by ASTA
Medica and 50% by BioNumerik. in the event only one of the Parties participates
in such litigation, then the Party participating in such litigation shall bear
100% of such Legal Expenses.

                                       22
<PAGE>
                  (c)   All recoveries from any Suit (including attorneys' fees)
and from all Other IP Litigation regarding the Product(s) in the Territory
(regardless of which Party actually receives such recovery) shall be applied
first in or toward satisfaction of all out of pocket expenses borne by ASTA
Medica and BioNumerik proportionately in connection with such Suit or Other IP
Litigation. If any surplus remains it shall be divided equally between ASTA
Medica and BioNumerik, provided that in the event that only one of the Parties
is responsible for the prosecution of a Suit or Other IP Litigation, then the
recoveries from such Suit shall be solely awarded or paid to such Party.

                  (d)   Each of ASTA Medica and BioNumerik shall give the other
Party full and complete access to all information such other Party reasonably
requests related to such Suits or Other IP Litigation

      10.   TRADEMARKS AND TRADEMARK RIGHTS.

            10.1  Registration, Maintenance and Ownership.

                  10.1.1   BioNumerik will use reasonable best efforts to obtain
one global trademark to be used for the Product(s), which is defined in this
Agreement as the "Product Trademark". BioNumerik will inform ASTA Medica at
intervals about the efforts of obtaining the Product Trademark. The choice of
Product Trademark will be made by mutual agreement of BioNumerik and ASTA
Medica. In addition to the foregoing, ASTA Medica will check its pool of
protected trademarks and will provide BioNumerik with potential Product
Trademark proposals if available. If ASTA Medica and BioNumerik select a
trademark for the Product(s) that is owned by ASTA Medica, ASTA Medica shall
grant and hereby does grant BioNumerik an exclusive royalty-free perpetual
paid-up license (with the right to sublicense) to use such trademark in all
parts of the world outside the Territory. If the Parties use a trademark for the
Product(s) that is owned by BioNumerik, BioNumerik shall grant and hereby does
grant ASTA Medica an exclusive royalty-free perpetual paid up license (with the
right to sublicense) to use such Product Trademark in all parts of the
Territory. Should no global Product Trademark be available or should a given
trademark be available but not be acceptable in some jurisdiction (e.g. for
linguistic reasons), the Parties will seek and reach agreement on an alternative
trademark for such jurisdiction. The ownership, use and licensing of such
alternative trademark shall be governed by the same provisions as those
contained herein regarding the ownership, use, and licensing of the Product
Trademark

                  10.1.2   BioNumerik agrees to register and maintain the
Product Trademark at the expense of BioNumerik for use in and association with
Product(s) and such other Trademarks in the Territory in respect of the
Product(s) as ASTA Medica and BioNumerik shall approve. ASTA Medica agrees

                                       23
<PAGE>
to assist in such registration, if requested by BioNumerik and to sell the
Product(s) only under such Trademarks as may be agreed to in writing with
BioNumerik.

                  10.1.3   ASTA Medica agrees that, except for Trademarks
selected from the ASTA Medica pool, as expressly provided in Section 10.1.1
above, and for the name and housemark (logo) "ASTA Medica" both in word and
word-and-design form, BioNumerik shall be the exclusive owner of all registered
and unregistered trademarks and/or service marks associated with the Product(s)
(collectively, "BioNumerik Related Trademark Rights"), including, but not
limited to the Trademarks and the "BioNumerik" name and housemark (logo).

                  10.1.4   BioNumerik shall remain free to use and grant rights
to the use of the Trademarks (a) outside of the Territory and (b) inside of the
Territory with respect to the "BioNumerik" name and housemark (logo) in
connection with products, activities and uses other than the sale and
distribution of Product(s).

                  10.1.5   ASTA Medica acknowledges the validity of the
BioNumerik Related Trademark Rights in the Territory. ASTA Medica shall take due
care not to do or cause to be done any action or omission which adversely
affects the validity of the BioNumerik Related Trademark Rights or jeopardizes
the maintenance thereof, either during the term of this Agreement or thereafter.

                  10.1.6   BioNumerik acknowledges the validity of the
trademarks selected from the ASTA Medica pool in and outside the Territory.
BioNumerik shall take due care not to do or cause to be done any action or
omission which adversely affects the validity of these trademarks or jeopardizes
the maintenance thereof, either during the term of this Agreement or thereafter.

                  10.1.7   ASTA Medica agrees that it will maintain the quality
control standards for the Trademarks and BioNumerik Related Trademark Rights set
forth by BioNumerik and agreed by ASTA Medica (ASTA Medica shall not
unreasonably withhold such agreement) and will ensure that any sublicensee using
the Trademarks and BioNumerik Related Trademark Rights in the Territory shall be
subject to similar standards of quality control.

                                       24
<PAGE>
      11.   IMPROVEMENTS.

            11.1  BioNumerik Improvements Included. During the term of this
Agreement, without any further payment, BioNumerik shall by the next Alliance
Steering Committee meeting fully disclose any BioNumerik Improvements to ASTA
Medica that have not previously been disclosed. In accordance with Section 2
hereof, BioNumerik has granted ASTA Medica an exclusive license to use the
BioNumerik Improvements in the Territory. Notwithstanding the foregoing,
BioNumerik shall, subject to the license grants contained in Section 2 hereof
and in accordance with such Section 2, be free to use any such BioNumerik
Improvements for its own purposes and for the benefit of its designated
Affiliates, assignees, sublicensees, and authorized users without any further
obligation to ASTA Medica, provided that any use of the BioNumerik Improvements
in the Territory shall not interfere with the exercise by ASTA Medica of the
rights granted to ASTA Medica pursuant to this Agreement.

            11.2  ASTA Medica Improvement Grantbacks. During the term of the
licenses granted herein, without any further payment, ASTA Medica shall by the
next Alliance Steering Committee meeting fully disclose any ASTA Medica
Improvements to BioNumerik that have not previously been disclosed. ASTA Medica
agrees to use all ASTA Medica Improvements for the purpose of supporting the
development and commercialization of Product(s) in the Territory in accordance
with this Agreement. In addition, ASTA Medica hereby grants BioNumerik a
non-exclusive, perpetual, worldwide except in the Territory and Japan,
royalty-free paid-up license to all ASTA Medica Improvements, and BioNumerik
(and its designated Affiliates and sublicensees) may, subject to the license
grants contained in Section 2 hereof, make, have made, use, sell and license
products and technology incorporating such ASTA Medica Improvements throughout
the world in areas outside the Territory, but excluding Japan. ASTA Medica
retains the right to practice such ASTA Medica Improvements other than in
connection with the Product(s) in the event of termination of the licenses
granted herein.

            11.3  Joint Improvements. Any new intellectual property jointly
conceived or reduced to practice by ASTA Medica and BioNumerik ("Joint
Improvements") shall be jointly owned by ASTA Medica and BioNumerik on an equal
basis, and all costs to file, prosecute, and maintain patent applications,
patents, and/or other applicable intellectual property protection regarding
Joint Improvements shall be shared equally by BioNumerik and ASTA Medica Each of
BioNumerik and ASTA Medica hereby agrees to license its interest in such
intellectual property in the manner provided in Sections 11.1 and 11.2.

                                       25
<PAGE>
            11.4  Sublicenses. Any sublicense by ASTA Medica of BioNumerik
Improvements or Joint Improvements shall require the prior written consent of
BioNumerik in the manner described in Section 2.3. Any sublicense by BioNumerik
of ASTA Medica Improvements or Joint Improvements shall require the prior
written consent of ASTA Medica, which will not be unreasonably withheld. Any
sublicense by either Party of Joint Improvements shall require the prior written
consent of the other Party, which shall not be unreasonably withheld.

      12.   CONFIDENTIALITY.

            12.1  Confidential and Proprietary Information. Each Party hereto
acknowledges that in order for BioNumerik and ASTA Medica to carry out their
respective obligations under this Agreement, it may be necessary for BioNumerik
and ASTA Medica to disclose to each other certain Confidential Information. Each
Party hereto agrees:

                  12.1.1   To ensure that it does not reveal or make available
any Confidential Information of the other to any third party, except as such
disclosure may be expressly authorized by this Agreement or otherwise
specifically approved in writing by the Party against whom such disclosure is
sought and to ensure that it will treat such Confidential Information of the
other Party in the same manner as it treats its own Confidential Information,
such treatment to be at least the degree that a reasonable person would perform
under similar circumstances;

                  12.1.2   To ensure that Affiliates, sublicensees, employees,
agents, associates or other persons to whom such disclosure may be made or who
may otherwise have access to such Confidential Information of the other have
agreed in writing to safeguard and maintain such Confidential Information of the
other;

                  12.1.3   To ensure that Confidential Information of the other
is not used for the receiving Party's benefit except as such benefits are
expressly contemplated herein;

                  12.1.4   To prohibit the Confidential Information of the other
from being duplicated in any manner; except as is reasonably necessary to
perform the tasks and obligations contemplated under this Agreement; and

                                       26
<PAGE>
                  12.1.5   To prohibit the Confidential Information of the other
from being published in any form without the prior express written consent of
the disclosing Party.

            12.2. Matters not included as Confidential Information.
Notwithstanding anything herein to the contrary, the defined term "Confidential
Information" and the obligations of nondisclosure, nonuse and confidentiality
relating thereto shall not include any information or data which:

                  12.2.1   Is or becomes known to the general public through no
action or fault of the receiving Party;

                  12.2.2   Was already known to the receiving Party without any
obligation of confidentiality prior to the date of disclosure hereunder or under
the ASTA Medica Confidentiality Agreement or the BioNumerik Confidentiality
Agreement, as the case may be, as evidenced by the written records of that
Party;

                  12.2.3   Is or becomes known to the receiving Party without
any obligation of confidentiality from a third party having the right to
disclose the same, and not having a confidential relationship with the
disclosing Party with respect thereto; or

                  12.2.4   Is necessary for the receiving Party or its
Affiliates to disclose to a governmental authority or any agency thereof on a
non-confidential basis, in order to pursue Government Regulatory Approvals or
other regulatory approvals as contemplated by this Agreement or for other
purposes related to the intent of this Agreement, provided, however, that the
receiving Party shall notify the disclosing Party before disclosing such
Confidential Information and shall take such actions as may be available to
restrict the extent of such disclosure and to obtain the protection of such
information to the extent possible.

            12.3  Survival of Confidentiality. The obligations of this Section
12 with respect to Confidential Information shall be in effect during the term
of this Agreement and shall continue indefinitely after the termination of this
Agreement.

      13.   PAYMENTS, RECORDS AND ACCOUNTING.

            13.1  Means of Payment. All payments due by the Parties to each
other under this Agreement shall be made by bank wire transfer in immediately
available funds to a bank account designated by the payee. All payments
hereunder shall be made in U.S. dollars.

                                       27
<PAGE>
            13.2  Currency. In the case of sales made, or costs incurred, in
currencies other than United States dollars, such amounts for payment of
royalties or other payments directed to BioNumerik shall be converted into
United States dollars using a monthly average of the officially published
conversion rate of the European Central Bank, Frankfurt, Germany.

            13.3  Access to Records.

                  (a)   Each Party shall keep (and shall cause its Affiliates
and sublicensees to keep) complete and accurate records and accounts regarding
the performance of its obligations under this Agreement. Such accounts and
records shall be kept at the principal place of business of the respective
Parties (or their Affiliates or sublicensees, as applicable).

                  (b)   Within 90 days after the end of each Fiscal Year, ASTA
Medica's accountant, KPMG, shall audit ASTA Medica's records and accounts
regarding the performance of ASTA Medica's obligations under this Agreement.
Following such audit, KPMG shall provide written confirmation to BioNumerik of
ASTA Medica's performance of its payment and related obligations hereunder.
BioNumerik shall be entitled to have BioNumerik's independent auditor perform an
audit of ASTA Medica's books and records on a confidential basis for the purpose
of confirming ASTA Medica's performance of its obligations under this Agreement,
provided that (i) one such audit may be conducted each year; and (ii) one
additional audit may be conducted each year upon a showing by BioNumerik of
reasonable cause for such audit and obtaining the prior written consent of ASTA
Medica, which consent will not be unreasonably withheld. BioNumerik shall pay
the cost of any such audits and each audit will be conducted so that it will not
disrupt ASTA Medica's ongoing business activities. If any such audit determines
a variation or error in the amounts paid or payable to any Party, the Party
owing such additional amount shall make prompt payment thereof to the other
Party within 45 days of such determination.

            13.4  Taxes and Required Withholdings. All taxes or related
governmental charges levied or assessed with respect to payments by ASTA Medica
to BioNumerik shall be borne by BioNumerik. ASTA Medica will support BioNumerik
to apply for tax reimbursements and/or tax exemption certificates from the
competent German or other tax authorities with respect to such payments.

                                       28
<PAGE>
      14.   DURATION AND TERMINATION OF AGREEMENT.

            14.1  Duration. The term of this Agreement shall commence upon the
date hereof and, unless otherwise terminated as set forth herein, the term of
this Agreement shall expire upon the later to occur of (i) the expiration of the
last to expire patent in the Territory relating to the Product(s) and (ii) 18
years after the date hereof. After expiration of the term of this Agreement
pursuant to clause (i) or (ii) of the preceding sentence, the licenses granted
by BioNumerik to ASTA Medica hereunder shall automatically become non-exclusive,
irrevocable, fully-paid licenses to use and/or sublicense the use of BioNumerik
Know-How to manufacture, use and sell Product(s) in each country in the
Territory where such license has previously been in effect. In the event one or
more countries are eliminated from the scope of the ASTA Medica license pursuant
to this Agreement, the license to ASTA Medica in Section 2 shall not apply to
such countries. In the event of expiration of this Agreement pursuant to this
Section 14.1, the obligations and rights of the Parties under this Agreement
shall terminate, except that the rights and obligations under this Section 14.1
and under Section 11 (Improvements), 12 (Confidentiality), 17 (Indemnification)
and Section 20.9 (Arbitration) shall survive and continue. In addition, the
rights of the Parties to use the ASTA Medica Data and Results and the BioNumerik
Data and Results shall continue as provided in Section 6.

            14.2  Termination.

                  14.2.1   The Parties hereto shall be able to terminate this
Agreement in the following events:

                           (a)   If a Party to this Agreement shall materially
breach, materially default or otherwise materially fail to perform under the
terms of this Agreement, the other Party may terminate this Agreement by giving
60 days advance written notice, unless the breach, default, or failure is cured
within such notice period.

                           (b)   If after Government Regulatory Approvals for
the Product(s) have been obtained, the Product(s) cease to have regulatory
authorization for their sale or distribution in all or substantially all of the
Territory, then either Party may terminate this Agreement upon 60 days advance
written notice, provided that a Party may not terminate this Agreement pursuant
to this clause (b) if the cessation of the Product(s) to have such regulatory
authorization was caused in substantial part by the actions or failure to act of
such Party;

                                       29
<PAGE>
                           (c)      If (1) a Party (the "Competitor Party")
proposes to allow or authorize a change in its ownership or control so that, as
a result of such change, such Party would be deemed to be a Competitor or an
Affiliate of a Competitor of the other Party, or (2) the ownership or control of
the Competitor Party changes so that, as a result of such change, such Party
would be deemed to be a Competitor or an Affiliate of a Competitor of the other
Party, then the Competitor Party shall give prompt written notice (the "Change
in Control Notice") to the other Party of such change or proposed change. If
requested by the other Party, the Parties shall negotiate for up to 60 days in
an effort to reach agreement that (i) such change in ownership or control will
not impair the Competitor Party's fitness and ability to perform in accordance
with the terms of this Agreement, and (ii) that such change in ownership or
control will not impair the business interests of the other Party. If the
Parties are not able to reach such an agreement within such 60 day period, the
other Party may terminate this Agreement upon 60 days advance written notice to
the Competitor Party. In addition to and notwithstanding the foregoing, in the
event the Competitor Party is ASTA Medica, then BioNumerik may request and shall
be granted a period (the "Evaluation Period") of up to 6 months following
receipt of the Change in Control Notice in which to make a determination as to
whether or not to terminate this Agreement. During the Evaluation Period, (1)
ASTA Medica shall continue to conduct all of its obligations hereunder regarding
development and commercialization of the Product(s), (2) BioNumerik may conduct
discussions with potential third party alliance partners for the Product(s) in
the Territory and may disclose information regarding the Product(s) to such
parties on a confidential basis, and (3) ASTA Medica shall provide reasonable
support and assistance in connection with BioNumerik's discussions with such
potential third party partners (including providing such information with
respect to the Product(s) as may be reasonably requested by BioNumerik and being
available for verbal discussions regarding the Product(s)). BioNumerik shall
have the right at any time prior to the end of such Evaluation Period to
terminate this Agreement upon 60 days advance written notice to ASTA Medica. In
the event of such a termination by BioNumerik, BioNumerik shall make the
reimbursements to ASTA Medica provided in Section 14.5 hereof, and ASTA Medica
shall transfer to BioNumerik the exclusive ownership of all information and
rights as provided in such Section 14.5.

                  14.2.2   If either Party shall become bankrupt or insolvent or
any proceeding is commenced to place its business in the hands of a receiver,
assignee or trustee in bankruptcy, or any proceeding is commenced for company
dissolution, or liquidation, whether voluntarily or otherwise, and such
proceedings are not dismissed within ninety (90) days of the commencement of any
such proceeding, then this Agreement shall automatically terminate to the extent
permitted by applicable law.

                  14.2.3   If, on the date that data package exclusivity,
granted by the EMEA upon approval of BNP7787 for marketing in Europe, for
BNP7787 expires in the European Union, no European Patents have been issued or
allowed that are included in the BioNumerik Patent Rights which protect the
marketing exclusivity of the Product, and which designate at least three of the
countries identified below (the "Major Countries"); then ASTA Medica may
terminate this Agreement upon sixty (60) days written notice to BioNumerik. For
purposes hereof, "Major Countries" means Germany, The United Kingdom, Spain,
France and Italy.

            14.3  Effect of Expiration or Termination. Termination is not the
sole remedy under this Agreement and termination of Product(s) rights or this
Agreement for any reason or the expiration of the term of this Agreement shall
not affect obligations or rights of either Party incurred or accrued prior to
such termination or expiration. The termination of Product(s) rights or this
Agreement shall not affect the right of any Party to recover damages from any
breach of this Agreement.

                                       30
<PAGE>
            14.4  Termination for BioNumerik's Breach, Change in Control or
Bankruptcy. In the event (i) ASTA Medica validly terminates this Agreement
pursuant to Section 14.2.1(a), Section 14.2.1(c), or Section 19.3 or (ii) this
Agreement terminates due to the bankruptcy, insolvency, receivership,
dissolution, or liquidation of BioNumerik pursuant to Section 14.2.2, then ASTA
Medica at its option upon written notice to BioNumerik at the time of such
termination may determine to either (a) continue to sell Product(s) in the
Territory, in which event all licenses granted to ASTA Medica (including the
right to use the BioNumerik Improvements) under this Agreement shall survive,
subject to ASTA Medica's continued obligation to pay royalties to BioNumerik
hereunder, or (b) cease selling Product(s) in the Territory, in which event all
rights of BioNumerik to use the ASTA Medica Improvements shall terminate and all
licenses granted to ASTA Medica hereunder shall terminate. In addition, if
requested by ASTA Medica in the event ASTA Medica determines to continue to sell
Product(s) in the Territory, (x) BioNumerik shall grant a non-exclusive license
to ASTA Medica under the BioNumerik Patent Rights, BioNumerik Know-How, and
BioNumerik Improvements to manufacture and have third parties manufacture
Product(s) for distribution and sale in the Territory, and (y) BioNumerik shall
also provide such information and reasonable assistance as may be necessary to
allow ASTA Medica and/or such third parties to manufacture Product(s) for
distribution and sale in the Territory.

            14.5  Termination for ASTA Medica's Breach, Change in Control or
Bankruptcy. In the event (i) BioNumerik validly terminates this Agreement
pursuant to Section 14.2.1(a), Section 14.2.1(c) or Section 19.3, or (ii) this
Agreement terminates due to the bankruptcy, insolvency, receivership,
dissolution, or liquidation of ASTA Medica pursuant to Section 14.2.2, then all
licenses granted to ASTA Medica hereunder and all rights to the Product
Trademark granted to ASTA Medica hereunder shall terminate, all rights to the
Product(s) shall automatically revert to BioNumerik, and ASTA Medica shall
cooperate with BioNumerik in all respects to effect the prompt and efficient
transfer to BioNumerik of product development and marketing activities for the
Product(s) in the Territory and all transferable elements of government
approvals, registrations, or other regulatory approvals and applications
relating to the Products(s) in the Territory. In the event of such termination,
ASTA Medica hereby assigns to BioNumerik all right, title and interest to all
regulatory filings, registrations, applications and approvals pertaining to the
Product(s) and the right to use the ASTA Medica Data and Results for the purpose
of developing and commercializing Product(s) in the Territory. In addition,
contingent upon such termination, ASTA Medica hereby grants to BioNumerik a
non-exclusive, royalty-free license under the ASTA Medica Patent Rights, the
ASTA Medica Know-How, and the ASTA Medica Improvements which are necessary or
useful for the manufacture, use or sale of the Product(s) as such product(s)
exist as of the date of such termination. BioNumerik's rights to

                                       31
<PAGE>
practice such ASTA Medica technology shall be limited exclusively to the purpose
of development and commercialization of products that would be Product(s)
hereunder. In addition to the foregoing, in the event this Agreement is
terminated by BioNumerik pursuant to Section 14.2.1(c) or Section 19.3, then
within 60 days of such termination, BioNumerik shall reimburse ASTA Medica for
(1) the license fees paid by ASTA Medica to BioNumerik pursuant to Section 5.1
hereof, and (2) all actual and reasonable research and development costs paid by
ASTA Medica and directly linked to the successful development and
commercialization of the Product(s) in the Territory. In addition, in the event
of such a termination by BioNumerik, ASTA Medica shall assign to BioNumerik
(and/or its designees) an exclusive, royalty-free, perpetual license in the
Territory under (a) the ASTA Medica Improvements, (b) the ASTA Medica Patent
Rights, (c) any rights to the Product Trademark owned by ASTA Medica, and (d)
all other information, findings, and developments, in each case as such
improvements, patent rights, trademark, information, findings or developments
may be developed or generated by ASTA Medica up to the date of such termination.
In addition, ASTA Medica agrees to provide all reasonable support and
assistance, including the preparation and signing of documents and instruments,
as may be requested by BioNumerik in order to further evidence or reflect the
rights to be transferred to BioNumerik pursuant to this Section.

            14.6  Termination Due to Cessation of Regulatory Authorization or
Lack of Patent Coverage. If this Agreement is terminated pursuant to Section
14.2.1 (b) or by ASTA Medica pursuant to Section 14.2.3, the obligations and
rights of the Parties under this Agreement (including all license grants) shall
terminate and all rights to the Product(s) shall revert to BioNumerik, provided
that the rights and obligations under Section 11 (Improvements), 12
(Confidentiality), 17 (Indemnification) and Section 20.9 shall survive and
continue. In addition, both ASTA Medica and BioNumerik shall retain the right to
use the Data and Results as provided in Section 6 and, in the event this
Agreement is terminated pursuant to Section 14.2.1 (b), BioNumerik and its
assignees and sublicensees may also use such Data and Results for the purpose of
seeking further Government Regulatory Approvals in the Territory following such
termination. In the event of termination by ASTA Medica pursuant to Section
14.2.3, ASTA Medica hereby assigns to BioNumerik all right, title and interest
to all regulatory filings, registrations, applications and approvals pertaining
to the Product(s) that are then in effect.

                                       32
<PAGE>
            14.7  Sale of Inventory. Upon valid termination of this Agreement by
BioNumerik pursuant to Section 14.2.1(a) , Section 14.2.1(c) or Section 19.3,
ASTA Medica may, to the extent permitted by applicable law, continue for a
period of up to 6 months to sell in the Territory Product(s) which it has in
inventory at the time of termination; provided, however, that any such sales
shall (i) be made at prices and under terms consistent with previous sales of
the Product(s) by ASTA Medica and (ii) be conducted in a manner so as not to be
harmful to BioNumerik or the market for the Product(s). Payments shall be paid
to BioNumerik in respect of all such sales as otherwise provided in this
Agreement. Except to the extent necessary to sell such existing inventory, ASTA
Medica shall immediately and permanently discontinue the use of the Trademarks
and take all steps necessary to confirm BioNumerik's ownership of such
trademarks and the Government Regulatory Approvals. In the event of such a valid
termination by BioNumerik, BioNumerik shall retain the exclusive right to use
the Data and Results.

            14.8  Country Specific Termination of Rights. If ASTA Medica does
not intend to sell Product(s) in a particular country in the Territory or if
ASTA Medica is not making reasonable ongoing efforts to commence selling
Product(s) in a particular country in the Territory, the license grants
contained in Sections 2.1 and 2.2 hereof shall terminate with respect to such
country in the Territory and such rights shall automatically revert to
BioNumerik. BioNumerik shall then be free to pursue the development, marketing,
sale and distribution of Product(s) in such country.

      15.   BIONUMERIK REPRESENTATIONS & WARRANTIES.

            In addition to the patent representations contained in Section 9.3,
BioNumerik represents and warrants to ASTA Medica as follows:

            15.1  Due Organization and Authority. BioNumerik represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of the State of Texas and has the corporate power
and authority to execute, deliver and carry out the terms and provisions of this
Agreement; (ii) that the execution, delivery and performance of this Agreement
by BioNumerik shall not require the consent of any third party, and shall not
cause a breach or violation under any fiduciary, contractual, statutory or
judicial obligation or restraint to which BioNumerik is subject or bound; and
(iii) that the person executing this Agreement on behalf of BioNumerik is duly
authorized to do so to bind BioNumerik.

                                       33
<PAGE>
            15.2  Safety of Product(s). BioNumerik represents and warrants that
is has not received any notification of, and has no knowledge that there is now
pending or that there have been any United States or other judicial or
administrative orders to ban the development or use of BNP7787, and BioNumerik
has no knowledge of any significant or material severe adverse reactions or test
results encountered or discovered regarding the use of BNP7787 which would
render BNP7787 unsuitable or unsafe for the purpose contemplated by this
Agreement, which have not been previously disclosed to ASTA Medica.

            15.3  Warranties on Quality of the Know-How. BioNumerik represents
and warrants to ASTA Medica that the BioNumerik Know-How provided by BioNumerik
under this Agreement is the technology currently utilized by BioNumerik in its
own manufacture, formulations and potential commercial uses of BNP7787.

            15.4  Governmental Agencies and Product Documentation. BioNumerik
represents and warrants that it has disclosed and made available to ASTA Medica
all pertinent correspondence received from any governmental agency, including
patent offices, that relates to or impacts on the ability to develop the
Product(s) hereunder in the Territory and will disclose all such further
information to ASTA Medica in the future. BioNumerik further represents and
warrants that, to the best of its knowledge, the documentation provided by
BioNumerik to ASTA Medica in connection with the Product(s) is accurate and
complete in all material respects and that no such documentation is
intentionally inaccurate or incomplete.

            15.5  Circumstances and Acts. BioNumerik represents and warrants
that it does not know of any circumstances and has not performed any acts that
are inconsistent with the terms or purposes of this Agreement or that may
infringe upon any of the rights of ASTA Medica hereunder.

      16.   ASTA MEDICA REPRESENTATIONS AND WARRANTIES.

            In addition to the patent representations contained in Section 9.4,
ASTA Medica represents and warrants to BioNumerik as follows:

            16.1  Due Organization and Authority. ASTA Medica represents and
warrants: (i) that it is a corporation duly organized, validly existing and in
good standing under the laws of Germany and has the full power and authority to
execute, deliver and carry out the terms and provisions of this Agreement; (ii)
that

                                       34
<PAGE>
the execution, delivery and performance of this Agreement by ASTA Medica shall
not require the consent of any third party and shall not cause a breach or
violation under any fiduciary, contractual, statutory or judicial obligation or
restraint to which ASTA Medica is subject or bound; and (iii) that the person
executing this Agreement on behalf of ASTA Medica is duly authorized to do so to
bind ASTA Medica.

            16.2  Right to Accept License; Due Diligence ASTA Medica represents
and warrants that it has the right, without any restrictions, to accept the
licenses set forth herein. ASTA Medica further represents that it has had the
opportunity to perform due diligence with respect to the Product(s) and has
performed such diligence to the satisfaction of ASTA Medica.

            16.3  Governmental Agencies. ASTA Medica represents and warrants
that it has disclosed and made available to BioNumerik all pertinent
correspondence received from any governmental agency that relates to or impacts
on its ability to develop the Product(s) hereunder in the Territory and will
disclose all such further information to BioNumerik in the future.

            16.4  Circumstances and Acts. ASTA Medica represents and warrants
that it does not know of any circumstances and has not performed any acts that
are inconsistent with the terms or purposes of this Agreement or that may
infringe upon any of the rights of BioNumerik hereunder.

      17.   INDEMNIFICATION.

            17.1  Indemnification by BioNumerik. BioNumerik hereby agrees to
indemnify, hold harmless and defend ASTA Medica from and against any and all
expenses, costs of defense (including without limitation attorneys' fees,
witness fees, damages, judgments, fines and amounts paid in settlement), and any
amounts ASTA Medica becomes legally obligated to pay because of any claim or
claims against it to the extent that such claim or claims (i) are due to product
liability claims arising out of Product(s) supplied to ASTA Medica by BioNumerik
other than to the extent such claims arose out of errors made by or directions
of ASTA Medica, (ii) arise out of manufacturing defects of the Product(s)
supplied by BioNumerik to ASTA Medica, (iii) are due to the non-compliance by
BioNumerik with applicable laws and regulations in the Territory, (iv) arise out
of the breach or alleged breach of any representation or warranty by BioNumerik
hereunder, or (v) are due to the negligence or willful misconduct of BioNumerik;
provided that (a) ASTA Medica provides BioNumerik with prompt notice of any such
claim and the exclusive ability to defend (with the reasonable cooperation of
ASTA Medica) and settle any such claim and (b) such indemnification shall

                                       35
<PAGE>
not apply to the extent such claims are covered by ASTA Medica's indemnity set
forth in Section 17.2 below.

            17.2  Indemnification by ASTA Medica. ASTA Medica hereby agrees to
indemnify, hold harmless and defend BioNumerik from and against any and all
expenses, costs of defense (including without limitation attorneys' fees,
witness fees, damages, judgments, fines and amounts paid in settlement) and any
amounts BioNumerik becomes legally obligated to pay because of any claim or
claims against it to the extent that such claim or claims (i) are due to the
non-compliance by ASTA Medica with applicable laws and regulations in the
Territory, (ii) result from ASTA Medica's activities under this Agreement, (iii)
arise out of the breach or alleged breach of any representation or warranty by
ASTA Medica hereunder, (iv) are due to the negligence or willful misconduct of
ASTA Medica, or (v) arise out of the possession, manufacture, use, sale or
administration of the Product(s) by ASTA Medica or ASTA Medica's Affiliates or
sublicensees (including, without limitation, the release, administration, or
shipment of any Product(s) that is adulterated or fails to meet applicable
manufacturing specifications); provided that (a) BioNumerik provides ASTA Medica
with prompt notice of any such claim and the exclusive ability to defend (with
the reasonable cooperation of BioNumerik) or settle any such claim and (b) such
indemnification shall not apply to the extent such claims are covered by
BioNumerik's indemnity set forth in Section 17.1 above.

            17.3  Mechanics. In the event that the Parties cannot agree as to
the application of Section 17.1 and 17.2 above to any particular loss or claim,
the Parties may conduct separate defenses of such claim. Each Party further
reserves the right to claim indemnity from the other in accordance with Section
17.1 and 17.2 above upon resolution of the underlying claim, notwithstanding the
provisions of Sections 17.1 and 17.2 above requiring the indemnified Party to
tender to the indemnifying Party the exclusive ability to defend such claim or
suit.

            17.4  Insurance Coverage. Each Party represents and warrants that it
is covered and will continue to be covered by a comprehensive general liability
insurance program that covers each Party's activities and obligations hereunder.
Each Party shall provide the other Party with written notice at least fifteen
(15) days prior to any cancellation or material change in such insurance
program. Each Party shall maintain such insurance program, or other program with
comparable coverage, beyond the expiration or termination of this Agreement
during (i) the period that any Product(s) is being commercially distributed or
sold other than for the purpose of obtaining regulatory approvals by ASTA Medica
or by a sublicensee, Affiliate or agent of ASTA Medica and (ii) a commercially
reasonable period thereafter.

                                       36
<PAGE>
      18.   RELATION OF THE PARTIES. The relationship between BioNumerik and
ASTA Medica under this Agreement is that of Parties to an arms-length negotiated
contract. Nothing in this Agreement is intended or is to be construed so as to
create between BioNumerik and ASTA Medica, respectively, the relationship of
partners, or joint ventures, or to establish either Party hereto as the employee
or agent of the other Party hereto. Neither Party hereto has an express or
implied right or authority under this Agreement to make any statement or
commitments of any kind or to assume or to create any obligations on behalf of
or in the name of the other Party hereto, or to bind the other Party hereto to
any contract, agreement or undertaking with any third party

      19.   ASSIGNMENTS.

            19.1  Assignment Restrictions. Subject to Sections 19.2 through 19.4
below, neither Party shall have the right to assign or delegate this Agreement,
or any of its rights or obligations under this Agreement without the other's
express written consent, such consent not to be unreasonably withheld, and said
assignment or delegation without such consent shall be null and void for all
purposes.

            19.2  Sale of Business. BioNumerik or ASTA Medica may assign its
entire interest in this Agreement provided that (i) such assignment is part of
the sale of all or substantially all of the assignor's business related to the
Product(s); (ii) notice of any contemplated assignment is given to the other
Party not less than 30 days prior to the effectiveness thereof; (iii) the
assignor delivers to the other Party a copy of the instrument, duly executed by
the parties thereto, effecting such assignment and affirming a complete
assumption by the assignee of the obligations of the assignor hereunder and a
recognition of the rights of the other Party, and (iv) if the assignment is to a
Competitor, the Parties shall also comply with the procedures set forth in
Section 19.3 prior to any assignment.

            19.3  Assignments to Competitors. In the event a Party receives an
offer from an outside party or proposes to assign this Agreement to a
Competitor, the assigning Party shall give the other Party written notice to
such effect and, if requested by the non-assigning Party, the Parties shall
negotiate for up to 60 days in an effort to reach agreement (i) that the
proposed assignee is at least the equivalent of the assigning Party with respect
to its fitness and ability to perform in accordance with the terms of this
Agreement and (ii) that such assignment will not impair the reasonable business
interests of the non-assigning party. If the Parties are unable to reach an
agreement as to such matters, the non-assigning Party may terminate this
Agreement upon 60 days written notice to the assigning Party following such
assignment. In addition to and notwithstanding the foregoing, in the event the
assigning Party is ASTA Medica, then BioNumerik may request and shall be granted
a period (the "Evaluation Period") of up to 6 months following receipt of the
written notice pursuant to this Section in which to make a determination as to
whether or not to terminate this Agreement. During the Evaluation Period, (1)
ASTA Medica shall continue to conduct all of its obligations hereunder regarding
development and commercialization of the Product(s), (2) BioNumerik may conduct
discussions with potential third party alliance partners for the Product(s) in
the Territory and may disclose information regarding the Product(s) to such
parties on a confidential basis, and (3) ASTA Medica shall provide reasonable
support and assistance in connection with BioNumerik's discussions with such
potential third party partners (including providing such information with
respect to the Product(s) as may be reasonably requested by BioNumerik and being
available for verbal discussions regarding the Product(s)). BioNumerik shall
have the right at any time prior to the end of such Evaluation Period to
terminate this Agreement upon 60 days advance written notice to ASTA Medica. In
the event of such a termination by BioNumerik, BioNumerik shall make the
reimbursements to ASTA Medica provided in Section 14.5 hereof, and ASTA Medica
shall transfer to BioNumerik the exclusive ownership of all information and
rights as provided in such Section 14.5.

                                       37
<PAGE>
            19.4  Assignment to Affiliates. Subject to Section 19.3, this
Agreement and the obligations hereunder shall be assignable, in whole or in
part, by BioNumerik, without consent of ASTA Medica, to one or more Affiliates
who shall affirm to ASTA Medica a complete assumption of the obligations
assigned; provided that BioNumerik shall guarantee the performance by such
Affiliate(s) of such obligations. Subject to Section 19.3, this Agreement and
the obligations hereunder shall be assignable, in whole or in part, by ASTA
Medica, without consent of BioNumerik, to one or more Affiliates who shall
affirm to BioNumerik a complete assumption of the obligations assigned; provided
that ASTA Medica shall guarantee the performance by such Affiliate(s) of such
obligations. The Parties hereby expressly recognize and agree that,
notwithstanding Section 19.3, if the oncology business unit (the "Oncology
Business Unit") of ASTA Medica shall become a separate legal entity, ASTA Medica
shall be permitted to assign this Agreement to the Oncology Business Unit upon
written notice to BioNumerik, provided that the ultimate ownership of the
Oncology Business Unit shall not have changed from the ultimate ownership of
ASTA Medica prior to such assignment, the Oncology Business Unit shall affirm to
BioNumerik a complete assumption of the obligations assigned, and ASTA Medica
shall guarantee the performance by the Oncology Business Unit of such
obligations.

      20.   MISCELLANEOUS.

            20.1  Regulatory Communications. Each Party agrees to notify the
other immediately by telephone (with prompt written follow-up) of any inquiry,
contact or communication received from any governmental regulatory agency or
other official body that materially and adversely relates to or impacts upon the
Product(s) or any component or ingredient thereof, and will promptly furnish the
other Party with copies of all written communications relating thereto sent to
or received from said regulatory agency.

            20.2  Adverse Effects. Each Party shall promptly inform the other in
writing of any material side effects or adverse effects, conditions or reactions
encountered by or reported to them in connection with the Product(s) which could
in any significant way render the Product(s) or any of the components thereof
unsafe or unfit. The Parties shall follow a written mutually agreed upon
procedure for communication of Adverse Events relating to the Product(s). These
procedures will be agreed to by the Parties prior to the initiation of clinical
trials in the Territory.

                                       38
<PAGE>
            20.3  Market Analysis and Marketing Reports. ASTA Medica shall
provide such analyses and reports as BioNumerik may reasonably request
describing the market for and performance of the Product(s) in the Territory,
the market position and promotion of the Product(s) in the Territory,
competitive product information including pricing and promotional information,
physician and consumer acceptance of the Product(s), and any technical,
promotional or other information developed or obtained by ASTA Medica which
could affect the Product(s) in the Territory or generally. To assist in the
distribution of Product(s) in the Territory, ASTA Medica shall regularly provide
BioNumerik with information and data that will enable BioNumerik to have a
complete update and better understanding of the general and specific markets
relating to the sale of Product(s) in the Territory under consideration. Such
Market Analysis and Reports should be provided and discussed at each Alliance
Steering Committee meeting. BioNumerik shall provide such analyses and reports
as ASTA Medica may reasonably request describing the market for and performance
of the Product(s) outside the Territory, the market position and promotion of
the Product(s) outside the Territory, competitive product information including
pricing and promotional information, physician and consumer acceptance of the
Product(s), and any technical, promotional or other information developed or
obtained by BioNumerik which could affect the Product(s) in the Territory or
generally. To assist in the distribution of Product(s) in the Territory,
BioNumerik shall regularly provide ASTA Medica with information and data that
will enable ASTA Medica to have a complete update and better understanding of
the general and specific markets relating to the sale of Product(s) outside the
Territory under consideration.

            20.4  Notice/Reports. Any reports, notices or other communications
required or permitted to be given by either Party hereto will be given in
writing by personal delivery, courier service or facsimile, or by registered or
certified air mail, postage prepaid, return receipt requested, addressed to each
respective Party at the address shown below.

                  If to BioNumerik:

                  BioNumerik Pharmaceuticals, Inc.
                  8122 Datapoint Drive, Suite 1250
                  San Antonio, Texas 78229
                  Attn:  Frederick H. Hausheer, M.D.
                  Facsimile No.: (210) 614-0643

                  If to ASTA Medica:

                  ASTA Medica Aktiengesellschaft
                  Weismullerstrasse 45
                  60314 Frankfurt am Main, Germany
                  Attn: Dr. Jose-Maria Gimenez-Arnau
                  Facsimile No. ++49/69/4001-2995

                                       39
<PAGE>
or to such other address as either Party may indicate by proper notice to the
other in the same manner as provided herein; provided, however, that the notices
referred to in or required under Sections 9.5 and 14.2. shall be given by
personal delivery, courier service, facsimile, or registered or certified
airmail mentioned above. All notices are deemed effective on the date of receipt
or, if delivery is not accepted, five (5) days after placement with the
addressee, an overnight courier service or a post office, as applicable.

            20.5  Severability. Should any provision of this Agreement be held
to be invalid, unenforceable, or against public policy, the remaining provisions
hereof shall not be affected thereby. In such event, the Parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the Parties as closely as possible with respect to those provisions,
which were held, to be invalid, unenforceable or against public policy.

            20.6  Counterparts. This Agreement may be executed in several
counterparts, each of which will be an original, but all of which, when taken
together, will constitute one and the same instrument.

            20.7  Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN SECTIONS
9 AND 15, BIONUMERIK MAKES NO WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS,
SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS
WARRANTIES OF MERCHANTABILITY, SAFETY, AND FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. THE PARTIES
UNDERSTAND AND AGREE THAT DEVELOPMENT AND COMMERCIALIZATION OF BNP7787 AND/OR
PRODUCT(S) WILL INVOLVE APPROVAL BY REGULATORY AUTHORITIES AND THAT NO PARTY IS
GUARANTEEING THE SAFETY OR EFFICACY OF BNP7787 AND/OR PRODUCT(S) OR THAT ANY
REGULATORY AUTHORITY OR AGENCY SHALL GIVE COMMERCIAL APPROVAL OF BNP7787 AND/OR
PRODUCT(S).

            20.8  Force Majeure.

                  20.8.1.  Except for the payment of money, no failure or
omission by the Parties hereto in the performance of any obligation of this
Agreement shall be deemed a breach of this Agreement nor create any liability,
if the same arises as a result of force majeure, i.e., any cause or causes
beyond the control of the Parties, including, but not limited to the following,
which for the purposes of this Agreement, shall be regarded as beyond the
control of the Party in question: acts of God; acts, omissions, rules,
regulations, or

                                       40
<PAGE>
orders of any governmental authority or any officer, department, agency or
instrumentality thereof; flood; earthquake; acts of the public enemy; war;
rebellion; insurrection; riot; invasion; strikes, or lockouts.

                  20.8.2.  In the event of such cause intervening, such excuse
of performance shall be only to the extent that such non-performance is beyond
the reasonable control of the Party bound by such covenant or obligation; and
the Party so affected shall use its reasonable best efforts to eliminate or cure
or overcome any of such causes and to resume performance of its covenants and
obligations with all possible speed.

            20.9  Arbitration. All disputes, controversies or differences which
may arise between the Parties, out of or in relation to or in connection with
this Agreement, or the breach thereof, shall be finally settled by arbitration,
by the International Chamber of Commerce (ICC) Rules in Genf, Switzerland in the
English Language, by a panel of three (3) arbitrators in accordance with the
then current ICC Rules, provided that the arbitrators will first render a
preliminary decision setting forth their grounds for decision and providing at
least thirty (30) days for each of the Parties to respond. The Parties hereto
expressly waive any right to appeal such decision or to challenge the decision
in any court. For purposes of enforcement, the judgment arising from such
arbitration may be entered in any court of competent jurisdiction in the United
States or Germany. This clause shall not be used to prohibit the right of either
Party to seek injunctive relief in appropriate circumstances.

            20.10 Export Controls. The Parties agree to abide by the United
States laws and regulations governing exports of the Product(s) or any other
technology developed or disclosed as a result of this Agreement. The Parties
acknowledge that any performance under this Agreement is subject to any
restrictions that may be imposed by the United States laws and regulations
governing exports. Each Party agrees to provide the other Party with any
assistance, including written assurances, which may be required by a competent
governmental authority and by applicable laws and regulation as a precondition
for any disclosure of technology by the other Party under the terms of this
Agreement. In addition, the Parties hereto agree to take all actions as may
reasonably be required to assure compliance with all applicable requirements of
the U.S. Foreign Corrupt Practices Act.

            20.11 Construction / Jurisdiction / Official Language. This
Agreement shall be construed in accordance with the laws of Switzerland. Each
Party hereto hereby irrevocably consents and submits to the jurisdiction of the
courts of the State of Texas and of the United States of America and of Germany
for purposes of enforcing any judgment that arises from arbitration pursuant to
Section 20.9. English shall be the official language of this Agreement and any
related agreement provided for hereunder and all

                                       41
<PAGE>
communications between the Parties hereto shall be conducted in that language.
Each Party recognizes that the Parties grant no license, by implication or
otherwise, except for the licenses expressly set forth in this Agreement. ASTA
Medica agrees to promptly provide BioNumerik with written English translations
of all important documents that are not in English and relate to the Product(s)
or this Agreement as may be reasonably requested by BioNumerik.

      21.   USE OF NAMES. The Parties hereto understand that each Party may
disclose certain matters pertaining to this Agreement as required by applicable
securities laws or other applicable laws and regulations, which disclosure may
include the name of the other Party and the subject matter of this Agreement,
and be in the form of public statements, whether oral or written, including, but
not limited to, shareholder reports, communications with stock market analysts,
press releases or other communications with the media. Each Party agrees to
coordinate with the other Party press releases and other public statements
regarding this Agreement and the Parties' relationship with regard to the
Product(s). Press releases and other public disclosure involving potentially
sensitive intellectual property matters, product development or marketing
strategies, clinical trials results or other sensitive information must receive
prior written approval by both Parties, which neither Party will unreasonably
withhold. Coordinated common major press releases will be mutually agreed to by
the Alliance Steering Committee in advance of such press release at the
international level. Local market information and abstracts from the common
press releases are not subject to further approval.

      22.   ENTIRE AGREEMENT. This Agreement comprises the entire understanding
and Agreement of the Parties hereto with respect to the specific subject matter
of this Agreement, and supersedes all prior Agreements or understandings,
written or oral, between the Parties hereto with respect to the specific subject
matter of this Agreement. In addition, those obligations under the BioNumerik
Confidentiality Agreement and the ASTA Medica Confidentiality Agreement shall
continue in full force and effect in accordance with their terms. This Agreement
may not be amended except by a written instrument signed by the Parties hereto.

      23.   CAPTIONS. The captions used in this Agreement are for purposes of
clarification only and are not meant to be construed as part of this Agreement.

                                       42
<PAGE>
      IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the day and year first written above.

ASTA Medica Aktiengesellschaft           BioNumerik Pharmaceuticals, Inc.

By:   /s/ BERND W. AUNDRUP               By:  /s/ FREDERICK H. HAUSHEER, M.D.
   -----------------------------------      -----------------------------------
      Bernd W. Aundrup                        Frederick H. Hausheer, M.D.
      Chairman of the Executive Board         Chairman & Chief Executive Officer

Date:   18 January 2001                  Date:  18 January 2001
     ---------------------------------        ---------------------------------

                                       43
<PAGE>
                   ATTACHMENTS TO STRATEGIC ALLIANCE AGREEMENT

ATTACHMENT A

      -     BioNumerik Patent Applications in the Territory

ATTACHMENT B

      -     BNP7787 Compounds

ATTACHMENT C

      -     Description and Definitions of Costs, Gross Profits, Gross Sales

                                       44
<PAGE>
                                  ATTACHMENT A

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       45
<PAGE>
                                  Attachment B

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       46
<PAGE>
                                  Attachment C

Further descriptions and definitions of financial terms, regarding the Costs,
Gross Profits and Gross Sales will be agreed upon by the Alliance Steering
Committee as soon as possible and may be amended from time to time by the
written agreement of the Parties.

                                       47
<PAGE>
FINANCIAL DEFINITIONS

GROSS SALES shall have the meaning contained in the Strategic Alliance Agreement
and shall include total sales at invoice values, not reduced by customer
discounts, returns or allowances or other adjustments in the Territory.

MANUFACTURING COSTS are the costs of buying raw materials and producing the
final packaged Product. Estimated at this time to be [**] of Gross Sales.
Manufacturing Costs shall include a reasonable overhead amount which shall be
calculated in accordance with U.S.GAAP.

SHIPPING COSTS are the costs of packaging and shipping the Product to the
customer. Estimated at this time to [**] of Gross Sales.

PRE-MARKETING COSTS are the costs associated with marketing the Product prior to
the product launch date, including branding and market research. Estimated at
this time to be [**] DM (est. [**] Euros) in [**] and [**] DM (est. [**] Euros)
in [**].

MARKETING COSTS are the costs associated with the ongoing promotion of the
Product. Estimated at this time to be, as a percentage of Gross Sales, [**] in
[**],[**] in [**],[**] in [**],[**] in [**] through [**], and [**] for all years
after [**].

SELLING COSTS are the commissions and allocated salespersons' salaries and
overhead. Estimated at this time to be, as a percentage of Gross Sales, [**] in
[**],[**] in [**],[**] in [**] and [**] for all years after [**].

EXTERNAL RESEARCH AND DEVELOPMENT COSTS are the costs associated with the
pre-clinical and clinical development of the Product in the Territory in
accordance with the Strategic Alliance Agreement. These costs will be paid
exclusively by ASTA Medica.

REGISTRATION COSTS are the costs associated with preparing the registration
document and submitting it to the various regulatory agencies in the Territory
in accordance with the Strategic Alliance Agreement. These costs will be paid
exclusively by ASTA Medica.

ADMINISTRATIVE COSTS are the costs associated with the administrative overhead
applied to the Product based on personnel effort actually spent on the project
in the Territory in accordance with the Strategic Alliance Agreement. These
costs will be paid exclusively by ASTA Medica.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

<PAGE>
FINANCIAL COSTS are the costs associated with the financial administrative
overhead applied to the Product, which consists of accounting and treasury costs
in the Territory in accordance with the Strategic Alliance Agreement. These
costs will be paid exclusively by ASTA Medica.

CONTRIBUTION MARGIN OR GROSS PROFITS shall consist of Gross Sales in the
Territory in accordance with the Strategic Alliance Agreement less the sum of
Manufacturing Costs, Shipping Costs, Pre-Marketing Costs, Marketing Costs and
Selling Costs.

CONTRIBUTION MARGIN SPLIT is the percentages of the Contribution Margin that
BNPI and ASTA Medica will receive for a given range of Cumulative Gross Sales.

BNPI CASH FLOW is the Contribution Margin multiplied by BNPI's Contribution
Margin Split in addition to the $15 million up-front payment. The BNPI
Contribution Margin Split is [**] for Cumulative Gross Sales up to [**],[**] for
Cumulative Gross Sales between [**] and [**], and [**] for Cumulative Gross
Sales over [**].

ASTA CASH FLOW is the Contribution Margin multiplied by ASTA Medica's
Contribution Margin Split in addition to payments by ASTA Medica of the $15
million up-front payment, External Research and Development Costs, Registration
Costs, Administrative Costs and Financial Costs. The ASTA Contribution Margin
Split is [**] for Cumulative Gross Sales up to [**], [**] for Cumulative Gross
Sales between [**] and [**] and [**] for Cumulative Gross Sales over [**].

NET PRESENT VALUE is the value of all cash inflows and cash outflows based on
jointly developed projection models. BioNumerik shall use a [**] discount rate
for such models and ASTA Medica shall use a discount rate in accordance with its
internal practices. The Alliance Steering Committee shall use a [**] discount
rate for such NPV models. ASTA Medica may use its own discount rate for such NPV
models as required.

PRODUCT CASH FLOW is Contribution Margin less External Research and Development
Costs, Registration Costs, Administrative Costs and Financial Costs.

CUMULATIVE GROSS SALES is the total aggregate Gross Sales from the date of
launch until the evaluation date.

Capitalized terms used but not defined herein shall have the same meaning
provided for such terms in the Strategic Alliance Agreement, dated January 18,
2001, between BioNumerik Pharmaceuticals, Inc. and ASTA Medica
Aktiengesellschaft (the "Strategic Alliance Agreement").

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>
(BIONUMERIK LOGO)

                                  July 14, 2004

Victor Miller
Director,
Global Business Development
Baxter Oncology
Baxter Healthcare S.A.
Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL  60015

Dear Victor,

         In connection with the Strategic Alliance Agreement (the "Alliance
Agreement") between BioNumerik Pharmaceuticals, Inc. ("BioNumerik") and Baxter
Oncology, I am writing to confirm that, so long as Baxter files a European
regulatory and marketing approval application for Tavocept(TM) within 6 months
after BioNumerik provides Baxter with BioNumerik's final clinical report and
data from the Tavocept Phase 3 clinical trial currently being conducted in the
U.S., Russia and the Ukraine in patients with metastatic breast cancer,
BioNumerik will not express an objection with respect to meeting the time
requirements of clause (b) of the third sentence of Section 8.2 of the Alliance
Agreement for Tavocept to receive Government Regulatory Approval (as defined in
the Alliance Agreement) in at least one country in Europe.

                                     Sincerely,

                                     Frederick H. Hausheer, M.D., F.A.C.P
                                     Chairman and Chief Executive Officer

cc:  Dr. Joy Anderson

            8122 Datapoint Drive, Suite 1250 o San Antonio, TX 78229
                      TEL: 210-614-1701 o FAX: 210-614-9439

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]